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Crosstalk between receptors allows for the integration of diverse and complex signalling pathways. 
Transactivation is a form of crosstalk between G-protein coupled receptors (GPCRs) and receptor 
tyrosine kinases (RTKs). RTKs are transactivated by GPCRs through two main mechanisms: 
ligand- independent intracellular pathways and triple membrane passing mechanisms involving 
GPCR mediated growth factor signaling.  
Transactivation has neuroprotective potential; however, the physiological relevance of this 
pathway is not known. Interestingly, some stressors can up- or downregulate GPCR and RTK 
activity, as well as initiate certain transactivation pathways, leading to the question: could 
transactivation be a stress response? Given the impact of stress on GPCRs and RTKs, this thesis 
directly explored the impact of stress, more specifically acute chemical stress, in the form of the 
stress hormone corticosterone and chronic stress, in the form of Chronic Early Life Social Isolation          
(CELSI), on the 5HT7-TrkB transactivation pathway.   
Another aim of this thesis was to analyze the effect of social isolation (CELSI) on the 
expression of proteins that are implicated in neuroplasticity and to explore if social isolation stress 
differentially primes the brain's response to stress or other stimuli. Coupling cell line based 
experiments with ex vivo tissue work, the overall aim of this thesis research was to gain a better 
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Signal transduction describes the way in which cells communicate and respond to signals within 
the environment. It is a fundamental and highly dynamic process, which is dependent on the 
effective transfer and integration of intra- and extra-cellular signals across a dense network of 
receptors and signalling molecules [1]. This thesis explores how stress, in the form of a 
pharmacological stressor (corticosterone) and a rodent model of early life adversity (chronic early 
life social isolation) affects the expression and/or activation of key receptors, and ultimately how 
these changes affect receptor crosstalk.  
1. Signal Transduction   
Signal transduction between different classes of receptors can take many forms; this crosstalk is 
necessary for neuronal function and survival [2]. One of these forms of crosstalk is called 
transactivation, wherein one receptor is observed to activate another receptor. Specifically, 
transactivation is defined as the transient activation of receptor tyrosine kinases (RTKs) by G-
protein coupled receptors (GPCRs) [3].  
1.1 G-protein coupled receptors (GPCRs)  
G-protein coupled receptors constitute the largest family of membrane receptor proteins, and 
approximately 70% of all clinically-used drugs target this family of receptors [4, 5]. GPCRs 
regulate cellular responses to neurotransmitters, hormones and environmental stimuli, and are 
implicated in basic physiological functions throughout all biological systems [4]. These membrane 
receptor proteins all contain seven transmembrane domains and are observed to interact with a 
heterotrimeric G protein complex at the C-terminus [6]. This heterotrimeric G protein complex is 
comprised of α, β and γ subunits, which are assembled in the inactive state [7]. Through the 
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exchange of GDP for GTP on the α subunit, the GPCR is activated, resulting in the cleavage of 
the α subunit from the βγ complex. The cleavage of this α subunit allows the receptor to bind 
various effector proteins [8, 9]. The α subunits are categorized into four main groups: Gαi is 
involved in the negative regulation of adenylate cyclase activity; Gαs stimulates adenylate cyclase 
activity; Gαq activates phospholipase C (PLC), and Gα12 activates Rho GTPases [10, 11]. 
Additionally, the βγ subunit has been shown to play an integral role in the activation or modulation 
of a range of signalling pathways [11, 12].   
This thesis will focus on two main GPCR families: serotonin (5HT) and dopamine receptors, 
with greater emphasis on 5HT receptors, and more specifically, the 5-HT7 receptor subtype. 
1.2. Serotonin  
Serotonin, or 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter that is synthesized 
from L-tryptophan [13]. The central 5-HT system originates in the midbrain and brainstem raphe 
complex, and sends efferents throughout the brain [14].  Serotonin helps integrate complex brain 
functions such as cognition, sensory processing, and motor activity. In addition, serotonergic 
signaling has been implicated in the modulation of emotional behaviors, including fear, anxiety, 
and aggression [14]. Though serotonin  is implicated in a variety of physiological functions, 
malfunction of its receptors (5-HT 1-7) or transporter (5HTT) is linked to a broad range of 
neuropathologies and mental illnesses [15]. The table below summarizes the roles, localization 
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↑ And ↓ indicate effect of agonist/receptor activation. Note: Some partial agonists are listed as agonists, and some 
inverse agonists are listed as antagonists. Abbreviations: 5-HT – 5-hydroxytrypamine; serotonin, NE – 
norepinephrine; noradrenaline; DA – dopamine, GABA – γ-aminobutyric acid, Glu – Glutamate, cAMP – cyclic 
adenosine monophosphate, PLC – phospholipase C, PKC – protein kinase C, Ca2+ – calcium ions. 
Table 1. An outline of serotonin receptor function and pharmacology [16-44]. 
 1.3. Dopamine Receptor  
Dopamine receptors are another class of GPCRs found in the vertebrate central nervous system 
(CNS). This class of GPCRs is implicated in the pathophysiology of neurological disorders like 
Parkinson’s, schizophrenia, Tourette’s, bipolar and Alzheimer’s disease [45]. There are five 
dopamine receptor subtypes, which are classified according to their homology and pharmacology. 
These subtypes are divided into two categories: “D1-like” (D1) and “D2-like” (D2) dopamine 
receptors. D1-like receptors constitute D1 and D5 receptors, whereas, D2-like receptors include 
short and long isoforms of D2, D3 and D4 receptors [45].  In terms of relative abundance in the 











































































































dopamine receptors within these two classes have significant amino acid sequence homology. 
Within the D1 class, D1 and D5 have 78% sequence homology; within the D-2 class, D2 and D3 
have 46% sequence homology and D2 and D4 have 53% sequence homology [46]. D1 receptors 
are localized in the striatum, nucleus accumbens, olfactory bulb, amygdala, hippocampus and 
substantia nigra, whereas, D5 receptors are localized in the cortex, substantia nigra and 
hypothalamus. For D2-like receptors, D2 receptors are localized in the striatum, ventral tegmental 
area (VTA), olfactory bulb and cerebral cortex, whereas, D3 receptors are localized in the striatum, 
islands of calleja and cortex, and D4 receptors are localized in the frontal cortex, amygdala, 
hypothalamus, and nucleus accumbens [45].  
 D1 class of receptors are Gαs-coupled, indicating that they stimulate adenylate cyclase 
activity, resulting in the subsequent increase of cellular cAMP. As such, these receptors are 
implicated in a variety of transduction pathways. For example, D1 receptors can modulate the 
electrochemical gradient in the striatum and kidney by inhibiting Na+-K+ ATPase through protein 
kinase A (PKA) and protein kinase C (PKC) signalling [47]. D1 receptors are also implicated in 
phospholipase C (PLC)-mediated increase of intracellular calcium, which can affect 
neurotransmitter release. In contrast, D2 receptors are Gαi-coupled, indicating that these receptors 
are involved in the negative regulation of adenylate cyclase activity. In addition, D2 receptors 
activate pathways that are implicated in cell proliferation like the MAPK and Akt pathways, 







1.4. Receptor Tyrosine Kinases (RTKs)  
Receptor tyrosine kinases (RTKs) play a significant role in the regulation of many biological 
functions, including  cell growth, differentiation, metabolism, and apoptosis [49]. RTKs are 
comprised of an extracellular ligand binding domain, a single transmembrane α-helix and a 
cytoplasmic tyrosine kinase domain. It is through ligand binding that  RTKs are activated, which 
induces dimerization and the autophosphorylation of multiple intracellular tyrosine residues within 
the binding domain [50, 51]. The resulting phosphotyrosines serve as docking sites for other 
proteins involved in signaling cascades [50]. Further, the phosphorylation of specific tyrosine 
residues creates docking sites for Src homology 2 (SH2) domain and phosphotyrosine (PTB) 
domain containing proteins, leading to the activation of signal transduction pathways [50]. More 
than one SH2 domain-containing protein can bind to an activated RTK at once, allowing for the 
simultaneous activation of multiple signalling pathways [50]. One major pathway activated by 
RTKs is the MAPK pathway. In this signal cascade, RTK activation leads to the activation of the  
membrane bound RAS protein, the activated RAS protein phosphorylates and activates MAPKKK 
that phosphorylates MAPKK, and MAPKK, in turn, phosphorylates MAPK, ultimately leading to 
transcriptional regulation [52]. In addition, another major pathway involves the Phosphoinositide-
3 Kinase, which phosphorylates inositol phospholipids in the cell membrane, subsequently leading 
to protein kinase activation [53].  
This thesis will mainly focus on three RTKs, namely: the tropomyosin kinase B receptor 
(TrkB), the platelet derived growth factor receptor (PDGFR) and the epidermal growth factor 





1.5. Tropomyosin Kinase B receptor    
Of the various RTKs is the tropomyosin kinase B receptor (TrkB), which belongs to the Nerve 
Growth Factor (NGF) family of receptors [54]. The TrkB receptor is largely expressed in the brain, 
with highest expression levels found in the cerebral cortex, hippocampus, thalamus, choroid 
plexus, granular layer of the cerebellum and the brain stem [55]. It is also expressed in the 
peripheral nervous system and in non-neuronal tissues such as the kidneys and the pancreas [55]. 
The TrkB receptor is activated by brain-derived neurotrophic factor (BDNF), but other 
neurotrophins, like neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4), also bind to the TrkB 
receptor, albeit with lower affinity [56]. TrkB has 3 isoforms: TrkB-FL, T1 and T-Shc, and while 
all three isoforms have the same extracellular and transmembrane domains, isoforms T1 and T-
Shc are truncated and therefore lack the tyrosine kinase activity of the TrkB-FL [57, 58]. The TrkB 
isoform T1 has been reported to negatively modulate the activity of TrkB-FL by forming 
heterodimers with TrkB-FL, and/or competing with it for neutrophin binding [57].  
The TrkB receptor regulates neuronal growth, survival, differentiation, development and 
synaptic plasticity [59, 60]. TrkB mediates growth and survival through the PI3K/Akt signalling 
pathway, neuronal differentiation and neurite development is mediated through the MAPK 
pathway and synaptic plasticity is mediated through the PLCγ pathway [61, 62, 63]. The TrkB 
receptor is implicated in the pathophysiology of mental illnesses and neuropathologies like 
depression, schizophrenia, Alzheimer's disease and Huntington's disease and the ability to regulate 
TrkB in these disease states could improve clinical outcomes[64]. Further, activating TrkB in the 
context of some neuronal insults has been shown to decrease neuronal damage [65]. Therefore, the 
ability to activate TrkB and other RTKs in neuropathological states has great neuroprotective 
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potential. As such, understanding how transactivation pathways, initiated by GPCR signaling, 
might promote TrkB signaling will aid in our understanding of this neuroprotective pathway.   
1.6. PDGF Receptor    
The platelet derived growth factor receptors (PDGFRs) are classified into two major subtypes, 
PDGFRα and PDGFRβ. PDGFRs are activated by PDGF ligands, which can exist as one of four 
isoforms and these ligands are observed to interact with the receptor as dimers [66]. The possible 
dimer compositions are as follows: PDGF-AA, -BB, -AB,-CC and –DD.  In addition, the PDGFRs 
subtypes, PDGFRα and PDGFRβ have differential affinity for the PDGF ligands, wherein, 
PDGFRα is observed to have a higher affinity for PDGF -A, -B and –C, whereas PDGFRβ tends 
to favor PDGF-B and -D [67]. PDGFRs are implicated in a variety of functions related to growth 
and development.  In particular, PDGFRs play a significant role in the development of the brain, 
kidney, cardiovascular and respiratory systems. As well, they are specifically implicated in bone 
formation, erythropoiesis, and angiogenesis. Lastly, PDGFRs play a dual role in health and 
disease; for instance, they are implicated in tumor growth and in the mechanism of inflammatory 
diseases, however they also contribute to wound healing [68, 69]. PDGFRs are involved in many 
cross-talk pathways, and more specifically, undergo transactivation by 5-HT and dopamine 
receptors.  
1.7. EGF Receptor 
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that belongs to the 
protein kinase superfamily comprised by three other members, erbB2/HER-2, erbB3/HER-3, and 
erbB4/HER-4. Six known agonists, including EGF and TGFα, activate EGFR; the activation of 
EGFR is observed to be the result of both ligand-dependent and ligand-independent mechanisms 
[70]. Interestingly, EGFRs show substantially increased basal signaling when over-expressed, 
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which underlies the role of this receptor in many cancers [71]. The EGFRs are implicated in a 
range of cellular functions, including: proliferation and survival, cell growth, apoptosis resistance, 
invasion, and migration. These outcomes are mediated through a variety of signalling pathways, 
namely, the Ras/Raf/mitogen-activated protein kinase pathway, the phosphatidylinositol 3-
kinase/Akt pathway, phospholipase Cγ, Signal transducers and activators of transcription pathway 
and Src kinase pathways [72]. In addition, EGFRs are implicated in many pathologies including, 
cancers and vascular pathologies and diabetes [73, 74, 75]. The EGFR is a key target to explore 
when considering the intersection of stress and transactivation.   
2. Transactivation: GPCR-RTK Crosstalk 
Transactivation is a form of GPCR-RTK crosstalk that has been characterized extensively in many 
in vitro models. This section will describe the transactivation pathway, focusing on the two main 
mechanisms: ligand-independent (depicted in Figure 1) and ligand-dependent transactivation 
(depicted in Figure 3).   
2.1. Ligand-independent transactivation 
Ligand-independent transactivation involves the activation of a GPCR followed by the 
downstream activation of various secondary messengers that result in the phosphorylation and 
activation of the RTK [76]. These pathways are completely intracellular and occur in the absence 
of the RTK ligand [76]. Proteins that regulate the phosphorylation status of RTKs include 
phosphotyrosine kinases (PTKs), which increase RTK phosphorylation levels (through direct 
phosphorylation) and protein tyrosine phosphatases (PTPs), which reduce RTK phosphorylation 
(through dephosphorylation) [10]. These enzymes exist in a fine balance, deviation from which, 
can affect the phosphorylation equilibrium of RTKs [10]. As a result, the intracellular mechanisms 
through with GPCRs transactivate RTKs target the activity of PTKs and PTPs. Several 
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intracellular signaling effectors are involved in intercellular transactivation. Of these intracellular 
signalling effectors, this thesis will focus on: (i) membrane associated non-receptor tyrosine 
kinases and (ii) reactive oxygen species (ROS).  
ROS induce transactivation through the inhibition of key phosphatases that 
dephosphorylate tyrosine residues, or by directly activating kinases through the modification of 
key protein-protein interactions, or triggering proteolysis of regulatory proteins that inhibit 
tyrosine kinase activity [77]. The combined effect of increased phosphorylation (due to increased 
PTK activity) and reduced dephosphorylation (due to inhibited PTPs) results in an overall increase 
in RTK phosphorylation and activation [10]. A study by Saito et al., demonstrated that hydrogen 
peroxide (a ROS) can transactivate the PDGF-β receptor at the Ty1021 site [78]. A variety of 
signalling pathways in the brain produce, or are modulated by, ROS activity, for instance, 
mitochondrial dysfunction and inflammatory responses, respectively [79, 80]. Since cellular stress 
can produce ROS, it has the potential to trigger transactivation. Given the neuroprotective capacity 
of RTK activation and the capacity of various cellular stressors or pathological states to produce 
ROS, transactivation could be an evolutionarily conserved mechanism to promote pro-survival 
signal transduction. 
 Additionally, ligand-independent transactivation can also be achieved through the activity 
of membrane associated non-receptor tyrosine kinases, most notably the c-Src family, specifically 
Src, Pyk2, and Fyn. These non-receptor tyrosine kinases are activated by GPCRs and they in turn 
directly phosphorylate RTKs [10]. 
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RTK transactivation, whether ROS mediated, or induced by non-receptor tyrosine kinases, 
is characterized by increased phosphorylation. This increased phosphorylation provides docking 
sites for the initiation of intracellular signalling cascades downstream of the RTKs, thus 
transactivation is able to “activate” a receptor in the absence of its ligand.    
Figure 1. Ligand-independent transactivation. The RTK is activated by the cognate GPCR through an 
intracellular, ligand independent mechanism. GPCRs can activate RTKs through: (1) the activation of 
membrane associated non-receptor tyrosine kinases e.g. c-Src that can directly phosphorylate the RTK OR 
(2) through the activation of NADPH oxidase, which releases reactive oxygen species (ROS). Increased 
ROS induces the inhibition of protein tyrosine phosphatases (PTPs) leading to enhanced phosphotyrosine 
kinase activity and subsequently increased RTK phosphorylation.  
 
2.1.1 Characterization of ligand-independent transactivation   
Our lab has previously characterized TrkB and PDGFβ receptor transactivation by several 5-HT 
and dopamine receptor ligands. We were able to demonstrate that in the human neuroblastoma-
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derived SH-SY5Y cell line, 5-HT transactivation of the PDGFβ receptor results in phosphorylation 
at Y1021, Y751 and Y1009 sites [56]. These phosphorylation events are transient with a peak at 5 
min and a return to baseline at approximately 15 min. As well, they are concentration-dependent, 
phosphorylation increases with increasing concentration of 5-HT, until 0.1 μM, after which it 
decreases [56].  
We were also able to demonstrate 5HT transactivation of the TrkB receptor in SH-SY5Y 
cells [81]. However, unlike the acute timeframe observed in PDGFβ receptors, transactivation was 
observed at 2 hours in TrkB receptors [81]. This demonstrates that even though receptors may 
undergo transactivation by a similar mechanism, many key factors, for instance, the time profile 
of transactivation and the required drug concentrations, may differ. As a result, characterizing 



















Figure 2. Proposed mechanism for PDGFβ receptor transactivation [82]. Proposed pathway for 
5HT-induced transactivation of TrkB and PDGFβ receptors. This mechanism was mapped based on the 






As shown in Figure 2, 5-HT can transactivate PDGFβ receptors and TrkB receptors. 
Upon GPCR activation, PLC is activated; PLC in turn induces intracellular calcium release, and 
the subsequent activation of PKC. NADPH oxidase subunits assemble to produce ROS. ROS 
(generated through NADPH oxidase production or applied exogenously) temporarily oxidizes 
and inactivates PTPs, hindering them from dephosphorylating RTKs including PDGFβ and TrkB 
receptors, thus leading to an increase in RTK phosphorylation [10]. 
 2.1.3 Transactivation is dependent on calcium, PLC, and PKC 
Calcium signaling is a common requirement for numerous transactivation pathways. For example, 
Tanimoto et al., showed that sphingosine 1-phosphate transactivation of PDGFβ was calcium-
dependent [83]. Previous work done in our lab to determine if 5-HT transactivation of the PDGFβ 
receptor is calcium-dependent demonstrated decreased receptor phosphorylation in cells that had 
been pre-treated with BAPTA-AM, an intracellular calcium chelator, whereas EGTA, an 
extracellular calcium chelator, did not have any effect on PDGFβ receptor phosphorylation [56]. 
This evidence suggests that transactivation is dependent on intracellular calcium. PLC and PKC 
were also investigated for their potential roles in this cascade. PLC cleaves the phospholipid, 
phosphatidylinositol 4, 5-bisphosphate (PIP2) to form secondary messengers inositol trisphosphate 
(IP3) and diacylglycerol (DAG) [84]. IP3 induces opening of calcium channels on the endoplasmic 
reticulum [85]. Calcium activates calcium-sensitive PKC isoforms at the plasma membrane where 
they also bind phophatidylserine and DAG to become fully activated [86, 87]. Cells pretreated 
with U73122, a PLC inhibitor, showed a reduction in RTK transactivation. Gö 6983, a PKC 
inhibitor also blocked transactivation by 5-HT. These results showed that transactivation was 




2.1.4 Transactivation is dependent on reactive oxygen species (ROS), NADPH, and PKC 
Earlier transactivation studies showed ROS dependency. For example, Chen et al., (2004) showed 
that H2O2 was required for RTK transactivation and downstream signaling [88]. Previous work 
done in our lab to determine if this mechanism was ROS-dependent demonstrated an attenuation 
of receptor phosphorylation in cells pre-treated with ROS scavenger, N-acetyl-L-cysteine (1000 
µM) [56]. To determine if NADPH oxidase function was necessary for transactivation, cells were 
treated with NADPH oxidase inhibitors, diphenyleneiodonium chloride (1 μM) and apocynin (100 
μM). Transactivation was indeed blocked by both molecules, suggesting that NADPH oxidase is 
a part of the cascade, and most likely the source of ROS [56]. Importantly, PKC is known to 
activate NADPH oxidase [88]. Taken together, the generation of ROS by NADPH oxidase is likely 
downstream of PKC activation, which is in turn activated after PLC activation [56].  
Thus far, we have discussed the general elements involved in ligand-independent 
transactivation, as well as the specific work previously conducted in our lab to characterize the 
mechanism of TrkB and PDGF transactivation by 5HT. The next section will focus on the other 














2.2. Triple membrane-passing signal (ligand-dependent transactivation) 
The second major mechanism of transactivation is ligand-dependent transactivation, or triple 
membrane passing signalling. Canonical triple membrane passing transactivation mechanisms 
involve the activation of matrix metalloproteinase (MMPs), as well as, a disintegrin and 
metalloprotease (ADAMS) and a disintegrin and metalloprotease with thrombospondin motifs 
(ADAMTs). These proteins cleave the extracellular matrix (ECM), resulting in the release of the 
various growth factors, cytokines, and chemokines that are bound to the ECM [89, 90]. GPCRs 
can trigger the activation of MMPs through the activity of secondary messengers, including Src, 
Pyk, and calcium. MMP activation leads to the release of RTK ligands and subsequent RTK 
activation [91]. This mechanism is called triple membrane passing, because the signal passes 
through the membrane thrice: first, an extracellular signal transduces an internal response (GPCR 
activation); second, an intra-cellular message is externalized (activation of MMPs and ADAMS), 
and finally, the external signal "crosses" the membrane once again leading to a cellular response 
(RTK activation) by ECM cleaved ligands [92].  
In summary, ligand-independent transactivation occurs in the absence of the RTK ligand 
and depends on an intracellular pathways to phosphorylate RTKs, either through the activity of 
non-receptor tyrosine kinases or through ROS inhibition of PTPs. On the contrary, in ligand-
dependent transactivation, the RTK ligand activates the receptor directly; however, this activation 
requires on the cleavage of the membrane-tethered ligands, which upon release bind to and activate 
the RTK. Of these two mechanisms, the findings of this thesis align with the ligand-independent 








Figure 3. Triple membrane-passing signal (ligand- dependent transactivation mechanism). The 
activated GPCR recruits a secondary messenger (e.g. c-Src, Pyk2, calcium, PKC or ROS) which leads to 
the activation of the MMPs, ADAMS resulting in the cleavage of the membrane bound pro-ligand. The 











3.1. Introduction to stress pathways  
Stress is defined as any phenomenon that affects the homeostasis of the cellular environment. It 
can be induced endogenously through the dysfunction or dysregulation of cellular mechanisms 
required for homeostasis or by external causative factors [93]. In response to stress, cells activate 
adaptive mechanisms to counter the imbalance caused by the stressor [94]. Though stress 
differentially affects various tissues and organ systems, there are some key evolutionarily 
conserved multi-organ stress responses. In the brain, one such pathway is the hypothalamic-
pituitary-adrenal (HPA) axis [94]. The HPA axis activation cascade involves the synthesis of 
corticotrophin-releasing factor (CRH) in the hypophysiotropic neurons of the paraventricular 
nucleus of the hypothalamus (PVN) [95]. CRH is released into the hypophyseal portal vessels that 
transport it to the anterior pituitary gland where it binds to its receptors inducing the release of 
adrenocorticotropic hormone (ACTH). ACTH in turn induces the release of cortisol/corticosterone 
(glucocorticoids) in the adrenal cortex [96]. The acute release of glucocorticoids is protective and 
activates the sympathetic nervous system, allowing the body to cope with the stressor. However, 
after a threshold concentration of glucocorticoids is reached, these glucocorticoids activate a 
negative feedback loop to inhibit the release of more CRH and ACTH [97]. 
In the brain, glucocorticoids bind the mineralocorticoid and glucocorticoid receptors. In 
the classic genomic pathway, once activated, cytoplasmic glucocorticoid receptors translocate to 
the nucleus where they regulate transcription. This genomic pathway can also be activated 
indirectly via membrane bound receptors and secondary messengers [97]. Recently, 
glucocorticoids have also been shown to have fast acting, non-genomic activity mediated through 
membrane bound receptors including GPCRs [98]. At the level of synaptic communication, 
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glucocorticoid action affects neurotransmission and ion channel activity through altering the 
release of excitatory amino acids and affecting the balance of key ions, like calcium [99]. 
Depending on its severity and frequency, stress can induce adaptive/ protective, or 
maladaptive responses. In the brain, acute glucocorticoid activation is adaptive and transiently 
promotes pro-survival signaling; however, chronic activation can induce negative results 
including, morphological and epigenetic changes, which can subsequently lead to pathological 
outcomes [100]. Acute stress typically enhances function through increasing synaptic 
transmission, long-term potentiation and learning for self-preservation. In contrast, mild chronic 
stress leads to the suppression of synaptic transmission, long-term potentiation, neurogenesis and 
dendritic remodelling. Further, severe chronic stress induces neurochemical distortions, impaired 
remodelling, mediates excitatory seizures, stroke, and head trauma [97].  
Additionally, the impact of stress in the brain can be transient and reversible. For example, 
repeated restraint stress in rats reduces dendritic branching in medial prefrontal cortical pyramidal 
neurons that is reversible after a period (3 weeks) without the stressor [101]. Conversely, stress 
may also result in long-term changes in neuronal signaling and significantly impact development 
and behavior; the timing of the stressor can significantly affect its impact [97, 102]. Various 
models of early life adversity have demonstrated that stress during the developmental phase can 
affect the organism's developmental trajectory and lead to negative health outcomes in adulthood 







3.2. RTK- Stress connection 
There is abundant evidence in the literature to establish a correlation between stress and altered 
regulation or activity of RTKs. RTKs, specifically the neurotrophin family of receptors, are 
implicated in neuroprotective signalling. Various models of stress, both in vivo and in vitro, have 
been shown to activate RTKs. In particular, genetic and pharmacological manipulation of the 
BDNF-TrkB pathway has revealed a prominent role in the susceptibility to, and development of 
depression, as well as recovery from depressive behavior [104].  
Various studies have demonstrated that elevated glucocorticoid secretion during chronic 
stress exposure is linked to the pathophysiology of depression, in part, by disruption of BDNF-
TrkB signalling and subsequent effects on synaptic function. Restoration of this signalling can 
reverse stress-induced cellular and behavioral pathologies and may underlie the response to a 
diverse array of antidepressants [105]. Corticosterone regulates the expression of both BDNF and 
TrkB mRNA in the hippocampus, a potential locus of stress-induced neurological deficits and 
antidepressant action [106]. Studies conducted by Schaaf et al. demonstrated that corticosterone 
administration decreases BDNF mRNA in a dose dependent manner in the CA1, CA3 and dentate 
gyrus. Additionally, they showed that at low corticosterone concentrations, TrkB receptor 
expression increases in the dentate gyrus and CA3 [107], therefore, suggesting that the impact of 
corticosterone is dependent on the administered concentration.   
Recently Barfield et. al., reported that corticosterone exposure in the ventral hippocampus 
of group-housed male wildtype C57BL/6 mice during adolescence can lead to the modulation of 
goal-directed actions and behaviors; this mechanism was demonstrated to be TrkB-dependent. In 
this study, corticosterone induced key changes in the ventral hippocampus, including a shift from 
full-length TrkB to the truncated (inactive) form in many corticolimbic brain regions and 
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diminishing the phosphorylation of the TrkB substrate extracellular signal-regulated Kinase 42/44 
(Erk 42/44). Administration of 7, 8-DHF (TrkB agonist) at doses that stimulated ERK42/22 
corrected the corticosterone induced behavioral abnormalities [108]. Additionally, TrkB-
dependent neurogenesis in the ventral hippocampus, as well as plasticity and activity of projections 
from this region to the prefrontal cortex, have been strongly implicated in the antidepressant and 
precognitive effects of ketamine [108].  
BDNF increases neurotransmission of glutamate through the PLC gamma pathway [109]. 
A study demonstrated that 24-48-hour corticosterone treatment inhibits BDNF-stimulated PLC 
gamma activity and BDNF-triggered glutamate release in cultured cortical neurons, showing the 
potential connection to impaired glutamatergic transmission in stress-induced models of 
depression [109]. Additionally, other RTKs have been shown to mediate stress signalling under 
pathological conditions. For example, the EGF receptor can trigger endoplasmic reticulum stress 
in cardiac damage and micro vascular damage in diabetes type 1. Further, mechanical stressors 
have also been shown to activate many cellular responses in an EGFR dependent manner [110, 
111].  These highlighted findings show the impact of stress on RTK signalling. 
In summary, the observation that pharmacological stressors applied in vitro such as 
corticosterone, as well as more severe or pathological forms of in vivo stress, such as those 







3.3. GPCR (5HT)-stress connection 
A correlation has been established between stress and serotonin function. For instance, upon acute 
stress exposure (such as a 5 minute forced swim stress test, or subcutaneous saline injection), 5-
HT metabolism is increased in various regions of the rat brain, including the amygdala and medial 
prefrontal cortex [112]. In freely moving animals, extracellular 5-HT concentration in the brain is 
elevated after the application of aversive stimuli, such as psychological stress, immobilization or 
exposure to novel environments [112]. The relationship between 5-HT levels and stress is of 
critical importance, considering the implications of the serotonergic system in stress-related 
psychopathologies, such as anxiety disorder, or major depressive disorder [113].  
As shown in Table 2, the seven 5-HT subtypes have differential responses to stress. 
Dysregulation of 5-HT1A receptors have been linked to psychiatric disorders, such as depression 
and generalized anxiety [114]. In fact, there is also evidence of 5-HT1A cross talk with RTKs in 
vivo in a genetic model of depression [115]. Stress hormones and glucocorticoid receptors may 
also modulate 5-HT1A receptor signaling [116]. Similarly, the 5-HT subtype, 5-HT2A receptor, has 
been implicated in specific features of stress-induced responses [117]. Previous studies have 
demonstrated that 5-HT2A receptors can enhance GABAergic neurotransmission, which is altered 
by stress [118].  Additionally, 5-HT3 receptor antagonists appear to be protective against long-
term stress-induced behaviors [119] and 5-HT4 receptor antagonists are also suggested to have 
anti-depressant properties [120]. Further, the 5-HT5A receptor displays coupling properties similar 
to the 5-HT1A receptor, and the 5-HT ligand [121]. However, details relating to the stress-induced 
behavioral consequences of serotonin signaling through 5-HT5A receptors is relatively unknown 
[122]. The 5-HT6 receptor agonists and antagonists have been proposed as possible means for 
treating psychiatric disorders such as depression [123].  
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As one of the more recently discovered serotonin receptors, the 5-HT7 receptor is the least 
characterized [124]. 5-HT7 mRNA levels are observed to increase following adrenalectomy in the 
CA3 sub-region of the hippocampus, indicating that glucocorticoids play a role in the regulation 
of the 5-HT7 receptor [125, 126]. Low doses of corticosterone replacement prevents this increase, 
suggesting that tonic control of 5-HT7 mRNA expression is affected by basal corticosterone levels 
in the hippocampus [125]. Alterations in serotonin release in the hippocampus and ventral striatum 
have been linked to 5-HT7 receptor expression, but more specifically, to be caused as a result of 
glutamate receptors on the raphe nuclei in these regions [127]. Recent studies have demonstrated 
that chronic restraint stress-induced endocrine disruption may also be associated with the increase 
in function and expression of 5-HT7 receptors [128]. It has been theorized that pharmacological 
blockades of adrenocortical 5-HT7 receptors could provide some therapeutic benefit for 
overcoming endocrine disruption in stress-related syndromes [128]. Moreover, activation of 5-HT7 
receptors in cultured hippocampal neurons increases glucocorticoid receptor expression in a PKA-
dependent manner [129]. The literature provides further evidence of the impact of stress on 
serotonin signalling.  
Further examples of the individual contributions of each subtype are briefly reviewed in 







RECEPTOR STRESSOR OBSERVED OUTCOMES 
5HT1A Forced swim test 
 
Decrease in 5-HT1A autoreceptors density in the 
presynapse and increase in postsynaptic 5-HT1A 
receptor labeling in the dorsal and medial raphe 
nucleus, and the hippocampus. 
 Corticosterone Decrease in potency of 5-HT1A agonist 8-OH-DPAT, 
resulting in the inhibition of 5-HT cell firing rate, in 
brain stem. 
5HT2A            Stress Impairment of 5HT2A receptor mediated facilitation 
of GABAergic synaptic transmission in the BLA. 
             Stress Regulation of brain-derived neurotrophic factor 
(BDNF). Increased expression in BDNF mRNA in the 
frontal and parietal cortex; decreased mRNA 
expression in the hippocampal dentate gyrus. 
5HT3 Chronic unpredictable stress Ondansetron (5-HT3 antagonist) demonstrated a 
reverse in: (i) chronic unpredictable stress-induced 
despair behavior in male rodents and a reduction in the 
time they spend immobile when subjected to forced 
swim test. (ii) Decrease in serotonin levels in the 
midbrain, prefrontal cortex and the cerebellum in 
chronically stressed mice  
5HT4  Forced Swim test  5HT4 agonists reduce immobility of rats subjected to 
the forced swim test.  
5HT5 NA Details relating to the stress-induced behavioral 
consequences of serotonin signaling through 5-HT5A 
receptors is relatively unknown 
5HT6 Unavoidable shock Long-term treatment of rats with ST 1936, a 5-HT6 
agonist protects from development of escape 
deficit(ED), but does not revert rats already in a state 
of chronic ED.  
5HT7 Chronic unpredictable stress Upregulation of 5-HT7 receptor mRNA expression in 
the hippocampus and hypothalamus of the rat brain  
 Acute restraint stress 
 
Increasing 5-HT7 receptor mRNA 
 halothane exposure 
 forced swim tests, 
 cold exposure, 
and restraint stress (for a period 
of one week) 
 
Small change in 5HT7 receptor mRNA 
 Repeated corticosterone 
administration 
 
Increased hippocampal 5HT7 receptor expression  
 
Table 2. An outline of the impact of stressors on 5HT receptor subtypes [112-129]. 
25 
 
In summary, there is abundant evidence to support the modulation of RTK signalling and 
GPCR signalling by stressors. Specifically, the effect of stress on BDNF-TrkB and 5HT signalling 
is relevant because of the reported physiological and behavioral outcomes. One of the questions 
this thesis sought to explore is, given that stress affects 5HT signalling and TrkB signalling, does 
stress modulate 5HT and TrkB crosstalk (transactivation)? Our depth of experience in the study of 
receptors and in 5HT and TrkB receptor crosstalk, coupled with strong evidence in the literature 
of stress effects on these receptors, provided me sufficient basis to connect the pieces of a puzzle 
and address the question of stress effects on 5HT-TrkB transactivation. Given the neuroprotective 
potential of RTK activation, and thus transactivation, it is important that we explore this question, 
to gain insight into the molecular interplay between stress and transactivation pathways. Given the 
recent discovery, and hence relatively limited characterization of the 5HT7 receptor, I chose to 
specifically study 5HT7 transactivation of TrkB.   
To my knowledge, I am the first to explore this specific question. Therefore, the following 
section provides both broad and specific evidence from various models and GPCR-RTK pairs to 











 4. Transactivation and Stress Connection  
Stress responses are diverse phenomena occurring at and coordinated between, many levels of 
organization within an organism, and are subserved at the cellular level by numerous interacting 
signaling pathways. Transactivation of RTKs represents a potential mechanism for the 
diversification and integration of signal transduction, as well as a method for the fine-tuning of 
effector recruitment [130-133].  
4.1. Glucocorticoid-mediated effects on transactivation 
The glucocorticoid receptor (GR) can transactivate Trk receptors in vitro via BDNF-independent, 
genomic mechanisms, as well as in the rat hippocampus via BDNF-dependent, nongenomic 
mechanisms, which may mediate glucocorticoid-induced enhancement of inhibitory avoidance 
memory [134, 135]. Altered BDNF-TrkB signaling appears critical for the expression of 
depressive phenotypes following chronic stress. Reduced BDNF-TrkB signaling is correlated with 
the development of depressive phenotypes; antidepressant response to pharmacologically diverse 
compounds involves enhanced activity in this pathway [136-141]. Importantly, diverse 
antidepressant drugs not only increase BDNF and TrkB phosphorylation, but may also 
transactivate TrkB in a BDNF- and 5-HT transporter-independent manner [138-140, 142]. The 
latter fact is particularly relevant, as several antidepressants have also been shown to increase GR 
activation as well [143-146]. As such, it is possible that GR-mediated transactivation of RTKs, 
particularly Trk neurotrophin receptors, may underlie both acute responses to psychological 





4.2. Acute stress mediated-effects on elements up- and down-stream of GPCRs and RTKs 
activation 
Transactivation has been observed following stimulation of a diverse array of GPCRs with 
neuromodulators and peptides, including monoamines and adenosine [133, 147-151]. Acute 
exposure to diverse psychological stressors has been demonstrated to elevate extracellular 
concentrations of monoamines and adenosine, among other transmitters, and chronic exposure 
may enhance their release in response to future stressors [152-156]. Moreover, GRs in the 
prefrontal cortex play a critical role in the enhancement of local dopamine released by stress [157]. 
While transactivation has been demonstrated in acute tissues, the concentrations required to induce 
it frequently exceed extracellular concentrations of neurotransmitters such as dopamine as 
measured by microdialysis, as is the case for PDGFRβ transactivation-induced NMDA receptor 
inhibition in the prefrontal cortex [158, 159]. Nonetheless, microdialysis has poor temporal 
resolution and fails to capture endogenous transients produced by phasic firing of dopaminergic 
neurons, which can yield dramatically higher concentrations similar to those that produce 
transactivation, albeit briefly [159, 160]. Indeed, stressors and aversive stimuli not only increase 
tonic dopamine, but also enhance phasic dopamine release [161, 162]. Notably, stress exposure 
may increase cAMP/PKA signaling in regions including the prefrontal cortex, at least in part by 
monoaminergic transmission [152, 163-164]. This is particularly relevant as even short pulses of 
GR agonists can induce delayed ligand-independent transactivation of TrkB in a transcription-
dependent manner in vitro, and signaling via Gαs-coupled monoamine receptors, or cAMP/PKA 
has been shown to enhance glucocorticoid-mediated transcription [165-168]. Consistent with this 
idea, both PKA signaling and GR-mediated TrkB transactivation have independently been 
identified as critical for glucocorticoid-induced enhancement of inhibitory avoidance memory and 
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GR-mediated antidepressant effects [143, 169, 170]. Whether these events individually, or by 
interaction, bring about RTK transactivation in vivo as part of a normal physiological stress 
response, however, remains to be seen. 
Hypoxia and ischemia may elicit even more dramatic increases in neurotransmitter 
concentration than psychological stress, particularly with respect to adenosine [171-174]. These 
insults also provide examples of stressors where transactivation is implicated in adaptive responses 
in vivo, most importantly within the brain [175]. Specifically, activation of the adenosine A1 and 
A2A receptors confer neuroprotective and neurotrophic effects via transactivation of EGF and Trk 
receptors and is similarly involved in cerebral ischemic preconditioning [175-177]. Similarly, 
transactivation of the EGF receptor by adenosine, acting via the A1 receptor, has been implicated 
in the cardioprotective effects of ischemic pre- and post-conditioning following later ischemia 
[178-180]. Additionally, cardioprotective roles for EGF receptor transactivation have also been 
described downstream of bradykinin B2 and δ opioid receptors as well [180-183].  
Transactivation of the TrkB neurotrophin receptor by the A2A and 5-HT7 receptor has 
similarly been implicated in the LTP-like increase in synaptic strength seen in the spinal phrenic 
nerve following some forms of intermittent hypoxia [184-188]. Such results lend credence to the 
idea that transactivation may be a critical component of many stress response mechanisms acting 
across levels of organization, particularly with respect to early adaptive responses that promote 
resilience. 
4.3. Chronic stress mediated-effects on elements up-and down-stream of GPCRs and RTKs 
activation 
In addition to acute stressors, many aspects of the neurobiological response to chronic stress 
involve signaling pathways that may also induce transactivation of various RTKs and regulate 
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neuronal survival. Specifically, neuroinflammation is frequently observed in, and critical to the 
pathology of, chronic stress, psychiatric disorders including depression, ischemia, and 
neurodegenerative disorders [189-194]. Inflammation involves a cascade of signaling events and 
biological responses, which, notably, include generation of ROS by NADPH oxidase and 
mitochondria [195]. In fact, the generation of ROS and impairment of antioxidant enzyme systems 
is associated with the pathological effects of glucocorticoid exposure and chronic stress, as well 
as the expression of depressive behavior thereafter [136, 191, 196-200]. Generation of ROS by 
NADPH oxidase and/or mitochondria have also been implicated in many transactivation 
mechanisms through the activation (or inactivation) of various redox-sensitive proteins, such as 
Src-family kinases in ligand-independent transactivation or metalloproteinases in some triple-
membrane passing transactivation [56, 201-208].  
4.4. Factors affecting transactivation 
Significant opportunity for transactivation to occur exists in both acute and chronic stress 
responses, but where these responses occur, when they are initiated, and whether they become 
disrupted or engaged at different stages of the stress response will determine the outcomes they 
confer. For example, although the GR can transactivate TrkB, chronic stress can decrease GR 
expression, thereby disrupting its interaction with TrkB and potentially producing stress-induced 
impairments [109, 208-210]. Both the glucocorticoid and 5-HT1a receptor, the latter a prominent 
target of antidepressants, have been reported to transactivate FGFR1 as part of signaling 
complexes, disruption of which were also identified in a genetic model of depression [115, 147, 
211, 212]. Another notable mechanism by which stress could disrupt transactivation is the 
alteration of mitochondrial ROS signaling. Ischemic preconditioning, as well as both RTK 
activation and transactivation in the heart and brain, frequently require mitochondrial ROS 
30 
 
generation, likely via opening of redox-sensitive mitochondrial ATP-sensitive K+ channels 
(KATP) [202, 213-219]. Such ROS-induced mitochondrial ROS release can spread through cells 
in waves, propagating the signal [220-222]. Thus, whether transactivation is initiated may depend 
upon the interaction of numerous factors, but this signaling paradigm also has the potential to yield 
widespread, multifaceted effects on cellular signaling and stress responses. 
To this point, we have discussed various stressors and models of stress that have been 
utilized to explore the impact of stress on GPCRs, RTKs and transactivation. The following section 














5. Chronic Early Life Social Isolation (CELSI) 
5.1. Early life adversity 
The period from birth to early adolescence is a very crucial phase in an organism’s development. 
In mammals, the early life phase is a time of rapid neural development [223]. A combination of 
genetic and environmental factors within this phase, govern an organism’s ability to relate with 
the surrounding world. In fact, a substantial body of evidence shows that stress during the 
developmental phase can lead to negative health and behavioral outcomes in adulthood [223]. 
Felitti et al., reported a strong correlation between the extent of exposure to childhood abuse and 
many health-related risk factors in adulthood [224]. For example, this study showed that people 
who had experienced four or more categories of childhood abuse, compared to those who had 
experienced none, had 4- to 12-fold increased health risks for alcohol use disorder, drug abuse, 
depression, and suicide [224]. Studies have also shown that stress in the first few years of life can 
impact an individual’s growth, intelligence, performance in skilled motor tasks and physical 
activity engagement [225]. Furthermore, a correlation has been established between childhood 
traumatic events and coronary artery disease, chronic pulmonary disease, cancer, and mental health 
problems [226]. Consistent evidence in the literature also suggests a link between early life 
adversity and later life onset of central sensitivity syndromes such as fibromyalgia or chronic 
widespread pain, headache or migraine, irritable bowel syndrome, temporomandibular join 
disorder, interstitial cystitis, endometriosis/vulvodynia and chronic pelvic pain [227]. This 
suggests that the impact of early life stress (ELS) is far reaching.  
One of the most pronounced outcomes of ELS is depression, or the increased risk of 
depression. A study showed that women with exposure to one or more childhood adversities, such 
as family violence, parent psychopathology or alcoholism, had a higher likelihood of developing 
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depression. The women in this study were also shown to have an increased probability for the 
onset of depression following exposure to lower stress levels, compared to women who had not 
experienced such adversity [228]. A similar clinical study showed that depressed participants 
report a significant amount of ELS compared to controls; in fact, 62.5% of individuals with major 
depressive disorder (MDD) reported two, or more traumatic early life events compared to 28.4% 
of controls. This early life trauma was shown to be related to experiences of interpersonal violence 
such as emotional, sexual and physical abuse [229].  
Overall, early life adversity has been shown to have detrimental effects in the human 
population, and many of these findings have been replicated in rodents using various models of 
early life adversity. Though the mechanisms underlying the impact of ELS have not been fully 
elucidated, various studies have traced these changes to molecular alterations at the 
genetic/epigenetic, protein or neurotransmitter level. These changes govern the observed 
behavioral differences and increased susceptibility to neuropsychopathologies [230]. For example, 
Wearick-Silva et al., showed that ELS can induce changes in Dopamine receptor D1 (Drd1) and 
Dopamine Receptor D2 (Drd2), BDNF exon IV and TrkB receptor gene expression in key brain 
regions, namely, the mPFC, hippocampus, cerebellum and motor cortex [231]. ELS has also been 
shown to induce early onset cognitive decline or Alzheimer’s disease, and it was shown that 
blocking glucocorticoid receptors rescued from this onset, which underlies the role of 
glucocorticoid receptors in stress related pathologies [232]. ELS has been shown to increase 
methylation in the NGF-1 gene, which regulates glucocorticoid receptor expression. Given that 
glucocorticoid activation regulates the negative feedback loop of HPA axis activation, attenuated 
GR expression results in less negative feedback, which in turn results in dysregulation of the HPA 
axis and increased levels of cortisol, CRH and ACTH [233]. Additionally, glucocorticoid receptors 
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have a low affinity for cortisol, so this binding is mainly facilitated under high levels of stress, 
which spike cortisol, therefore resulting in the compensatory downregulation of glucocorticoid 
receptors [97]. Therefore, as explained above reduced GR expression in the hippocampus would 
lead to a prolonged stress response as well as an increase in its magnitude. As a result, individuals 
with attenuated glucocorticoids have increased sensitivity to given stressors. 
5.2. Chronic Early Life Social Isolation (CELSI) 
Exposing mammals to social isolation and other adverse events in early life has been shown to 
have a significant impact on brain development and adult behavior [223]. Though the 
physiological and molecular mechanism(s) underlying these outcomes have not yet been fully 
elucidated, it is important to understand the capacity of chronic early life stress to alter the 
neurochemistry of the developing brain and explore the mechanism by which it does so.  
In rodent models, pre- and post- weaning social isolation has been shown to induce 
behavioral changes, for example, increased locomotor activity in response to novel environments, 
increased responsiveness to psychostimulants and altered sensorimotor gating of the acoustic 
startle response [234, 235, 236]. Social isolation has also been reported to induce changes in the 
density and function of a variety of receptor-neurotransmitter systems in the brain [236, 237], 
subsequent sections will elaborate on some of these systems.  
5.3. Behavioral changes in socially isolated rats 
The behavioral changes observed in socially isolated rats, correlate to the behavioral phenotypes 
seen in human neuropsychological disorders, such as schizophrenia and depression. Previous 
studies reveal that socially isolated rats do not habituate normally when placed in a new 
environment, these rats exhibit motor hyperactivity and spend less time resting, compared with the 
group housed controls [223]. Furthermore, an abnormal expression of immediate early genes and 
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genes regulating cell differentiation and apoptosis have been observed in the pre-frontal cortex of 
these rats [238] which implies that abnormal PFC activity may be involved in this behavioural 
alteration. These behaviors are characteristic of the positive symptoms of schizophrenia and/or the 
‘anxiety’ accompanying depression [239].   
Pre-pulse inhibition (PPI) is a phenomenon in which a pre-stimulus, with a weaker signal, 
inhibits the response to a stronger signal. There is a strong co-relation in the neurobiology of PPI 
in humans and rodents [223]. PPI impairments likely reflect stimulus overload-induced cognitive 
fragmentation, and are characteristic in psychiatric disorders such as depression and schizophrenia 
[223]. Studies have shown that PPI impairments induced by social isolation can be reversed by, 
M100907 (selective 5-HT2A receptor antagonist) in rats, and MKC-242/ozemozotan (5-HT1A 
agonist) in mice [240]. 
5.4. ELS and TrkB/BDNF 
As mentioned, brain-derived neurotrophic factor (BDNF) activates the TrkB receptor, and is 
involved in the regulation of proliferation, differentiation and survival of neuronal and non-
neuronal cells in the CNS [223]. The neurotrophic factor theory of depression speculates that a 
decrease in BDNF is correlated with depression. In fact, BDNF has been shown to have 
antidepressant properties [241]. A study by Russo-Neustadt et al., showed that BDNF mRNA is 
up-regulated with chronic antidepressant treatment [242, 243]. These findings imply that chronic 
stress, or circumstances that have the capacity to induce relative levels of depression, will 
potentially affect the expression of BDNF and TRKB receptor in the brain.  
In a similar trend, post-weaning social isolation has been reported to induce a decrease in 
BDNF levels in rats, suggesting that social isolation may induce depressive behaviors [260]. 
Further, in rats, stressful experiences such as immobilization have the capacity to reduce BDNF 
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mRNA expression up to 75% in the hippocampus [244]. However, re-exposure to cues previously 
associated with pain, for instance foot shock, reduces BDNF mRNA expression by about 21% 
[245]. A study conducted by Barrientos et al. observed that social isolation for 6 h was sufficient 
to cause a drastic decrease in BDNF mRNA in the dorsal and ventral dentate gyrus (60–80%), as 
well as the CA3 region (about 50%) of the hippocampus[244]. Additionally, we have shown that 
the activation of 5-HT7 receptors increases TrkB receptor expression. This observation may in 
part explain the ability of antidepressants (which prevent 5-HT reuptake) to promote TrkB/BDNF 
signalling [81]. 
5.5. ELS and 5-HT 
5-hydroxytryptamine 5-HT is involved in excitatory and inhibitory neurotransmission [246]. Early 
life social isolation has been reported to alter the expression of 5-HT receptor in various regions 
of the brain. A study by Bibancos et al. showed that the gene expression  of 5-HT receptor 
subtypes, 5-HT(1A), 5-HT(1B), 5-HT(2A), 5-HT(2C), 5-HT(3A), 5-HT(6) and 5-HT(7), were 
reduced in the pre-frontal cortex; 5-HT(1B), 5-HT(2A) and 5-HT(2C) were also shown to be 
reduced in both hypothalamus and midbrain. In contrast, the only alteration in the hippocampus 
was 5-HTR (6) overexpression [247]. A study by Preece et al., reported an increase in 5-HT2A 
binding in prelimbic, motor and cingulate cortices. They also reported reduced 5-HT1A binding 
in the prelimbic cortex but increased binding in the hippocampus [248]. A study by Muchimapura 
et al., showed that social isolation alters presynaptic 5-HT1B not the post-synaptic hippocampal 






5.6. ELS and NMDA 
The N-methyl-D-aspartate (NMDA) receptor is a glutamate receptor that is implicated in both 
normal and pathological functions in the brain [250]. The NMDA receptor is a major regulator of 
neuroplasticity, playing a central role in functions like learning and memory, however, excessive 
activation of the NMDA receptor is associated with the pathophysiology of CNS injury syndromes 
like hypoxia-ischemia and as well as illnesses like schizophrenia [251, 252]. The NMDA receptor 
is a tetramer, comprising of the obligatory GluN1 subunits and the modulatory GluN2 (A-D) or 
GluN3 (A and B) subunits [253]. Various forms of stress, including ELS, can modulate glutamate 
levels, thus making the NMDA receptor a relevant target to explore [254]. Acute stressors have 
been shown to induce an increase in NMDA surface expression. Further, a study conducted by 
Turnock et al. reported a 1.26-fold increase in GluN2A transcripts in the prefrontal cortex of 
socially isolated rats [255]. Additionally, Zhao et al., showed up-regulation of GluN2A and 
GluN2B receptors in the hippocampus in socially isolated animals. These studies highlight the 
impact of stress on NMDA expression [256] 
This evidence from NMDA, 5-HT, TrKB and BDNF studies show that the stress induced 
by social isolation can trigger changes in the neurochemistry of the brain, which could lead to 
adverse outcomes like depression and schizophrenia. Social isolation is a form of chronic stress; 
therefore, one can deduce from these findings that chronic stress has the capacity to induce changes 
in the brain during development. We seek to analyze the effect of social isolation on the expression 
of TrkB, BDNF, and the GluN2B subunit of the NMDA receptor. Observing and analyzing the 
changes that occur in these major signalling pathways will lead to a better understanding of the 
neurochemical changes that occur when a developing brain is exposed to chronic stress. 
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The next section, chapter 2, focuses on the characterization of transactivation in HT22 cells 
and ex-vivo brain slices, thus laying a foundation for further transactivation and stress studies. 
Chapter 3 explores the impact of CELSI on the expression of plasticity related proteins, namely, 
the TrkB receptor and the GluN2B subunit of the NMDA receptor, thus laying a foundation for 
further studies in which I explore the impact of various treatments on receptor expression in CELSI 
slices. Finally, chapter 4 explores the impact of pharmacologic manipulation of 5-HT7 and 
glucocorticoid receptors using LP12, CORT and CORT+LP12 treatment on TrkB-Y816 receptor 
activation, as well as TrkB receptor and GluN2B receptor expression. The work in chapter 4 
allowed me to explore key questions, for instance, does CELSI affect transactivation? In addition, 


















The activation of RTKs by GPCRs that occurs in the transactivation pathway facilitates signal 
integration through connecting two independent signalling cascades [10]. Though the 
transactivation pathway has been subject to extensive research since its discovery 25 years ago, 
some questions remain unanswered.  For example, the exact in vivo role, or physiological relevance 
of this pathway remains to be elucidated [3, 10]. Despite these gaps in understanding, this pathway 
has garnered a great deal of interest because it has therapeutic potential, which is largely related to 
its capacity to induce RTK activation. The activation of RTKs is neuroprotective against a variety 
of neuronal insults [257]. However, the large size of RTK ligands limits their ability to cross the 
blood-brain-barrier and poses a challenge to harnessing this neuroprotective potential in vivo. As 
a result, transactivation offers a potential means to bypass this challenge and harness the 
neuroprotective potential of RTKs.  
2.0 Introduction 
The transactivation pathway has been most extensively studied in cell lines, and most 
predominantly in HEK293 cells. Recently, the Beazely lab demonstrated crosstalk between 5HT 
and PDGF receptors, as well as 5HT and TrkB receptors, in the SH-SY5Y cell line [56, 76, 81, 
82]. Characterizing the above-mentioned pathway in the SH-SY5Y cell line provided a platform 
to transition these studies to more physiologically relevant models, such as, the HT22 cell line and 
ex vivo slices.  
The HT22 cell-line is a murine-derived hippocampal cell line, which, due to its tissue 
origin, is a physiologically relevant model to explore neuronal processes such as transactivation 
[258]. Cell lines in general are robust models to explore signalling pathways, due to their relative 
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ease of maintenance, their rapid growth/turnover and the relative cost-effectiveness [259]. 
However, in these in vitro models, many environmental factors are highly controlled (e.g. 
temperature, humidity, PH, media composition). As such, there is some deviation from the 
dynamic nature of an in vivo environment, which can limit the degree of translation or replicability 
between in vitro and ex vivo studies. Additionally, receptor expression may differ between cell 
lines and animal, or human tissue [259].  Therefore, to gain a greater understanding of how the 
current in vitro findings relate to in vivo realities, the decision was made to study transactivation 
using ex vivo brain slices.  
The overall aim of this thesis is to explore the relationship between transactivation and 
stress, and specifically, exploring the impact of psychosocial and pharmacological stressors on the 
transactivation pathway. In alignment with this overall aim, a sub-aim was to replicate 
transactivation both in cell lines and the ex vivo slice model reliably, in order to establish a viable 
model in which to explore the effect of stress. This chapter highlights foundational data exploring 
transactivation by comparing outcomes of different GPCR-RTK pairs. Additionally, the impact of 
a pharmacological stressor on RTK activation and/or expression was explored, and, lastly, the 
outcomes of combined transactivation and stress treatment on RTK activation was evaluated. 
Through the characterization of various GPCR- RTK transactivation partners, this study was an 







2.1. Study objectives 
2.1.1 Replication of transactivation 
The primary aim of this study was to replicate transactivation (increased RTK phosphorylation 
relative to control) reliably in the HT-22 cell line and in ex vivo brain slices. To achieve this aim, 
many GPCR agonist-RTK partners were used to screen for TrkB and PDGF receptor activation: 
5-HT hydrochloride (general serotonin receptor agonist), 8-OH-DPAT (full 5-HT1A receptor 
agonist/partial 5-HT7 receptor agonist), LP12 hydrochloride (selective 5-HT7 receptor agonist), 
and quinpirole (Dopamine 2/3 receptor agonist). The main objective was to identify the most 
reliable GPCR-RTK candidate to carry forward into transactivation-stress studies, as well as to 
identity the best model (cell line vs. ex vivo slices) to proceed with. 
2.1.2 Exploring pharmacological stress effects on RTKs 
Given that the secondary goal of this study was to provide preliminary evidence for the impact of 
stress on transactivation, the second aim was to explore in naïve (non-stressed) brain tissue, how 
corticosterone (CORT), a pharmacological stressor, affected RTK activation. In simpler terms, 
does this pharmacological stressor affect baseline RTK activation? 
2.1.3 Combined treatment (transactivating GPCR agonist and pharmacological stressor)  
After achieving the above aims, the third aim was to explore the outcomes of a combined treatment 
of a transactivating agonist and corticosterone. The rationale being: (i) if the transactivating agonist 







2.1.4 Region differences 
Brain slices from different regions: the hippocampus (HP) and prefrontal cortex (PFC) were used 
to explore if there were region specific differences.  
2.1.5 Corroborating proteins (Src and Erk activation) 
If RTK transactivation was observed, the activation of proteins and second messengers implicated 
in RTK transactivation as well as downstream signaling would also be expected.  Using that line 
of reasoning, the final aim was to measure the activation of protein messengers upstream, or 
downstream of the RTK transactivation.  
2.2. Hypotheses 
In accordance with the aims, the following was hypothesized:   
1. Based on previous findings with SH-SY5Y cells, I expected that the treatment of ex vivo 
brain slice tissue and/or HT-22 cells with GPCR agonists (5-HT hydrochloride (5-HT), 
LP12 hydrochloride (LP12), quinpirole and 8-OH-DPAT) would result in transactivation 
of TrkB and PDGF receptors, measured by an increase in tyrosine phosphorylation above 
baseline.  
2. Based on various reports in the literature that showed that treatment of cells with CORT 
can induce RTK activation through unknown mechanisms [97], I anticipated that CORT 
treatment would increase RTK activation above baseline.  
3. Based on the previously stated hypotheses that I would: (i) observe transactivation and (ii) 
that CORT would induce an increase in phosphorylation greater than baseline, I anticipated 
that the combined treatment with a transactivating GPCR agonist and CORT would result 
in either additive or synergistic effects.  
42 
 
4. The HP and PFC are differentially innervated and have different levels of receptor 
expression, among other differing factors, to support their respective functions [260]. 
Given that, I expected that the transactivation, or CORT-induced outcomes observed in 
these two regions would not present an identical profile, but would differ either in direction, 
or in magnitude. 
5. In light of the classical mechanisms of receptor activation and signal transduction, I 
anticipated that if I observe transactivation, I would also observe the activation of proteins 
that activate, or are activated down-stream of, the RTK. 
2.3 Materials and methods  
2.3.1 Cell culture and western blot 
HT22 cells were cultured in DMEM and HAM's F12 (1:1) (Fisher #SH20361), 10% fetal bovine 
serum, 100 U/ml penicillin and 100 μg/ml streptomycin. Cells were maintained at a temperature 
of 37°C in a humidified atmosphere of 95% air and 5% CO2, and media was changed every 3-5 
days. Cells were trypsinized with 0.25% trypsin/0.1% EDTA, and passages 1-12 were used. For 
drug treatments and experimentation, the cells were seeded in full growth media for 24 h and once 
they reached 80% confluency, they were differentiated in neurobasal media (Gibco, Life 
Technologies) containing N2 supplement and 2 mM L-glutamine for an additional 24 h. Drug 
treatments were performed in neurobasal media. 
After drug treatment, cells were washed with phosphate-buffered saline (PBS) and lysed 
in chilled lysis buffer (20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 30 
mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, and 1% 
Triton X-100; supplemented with Halt Protease and Phosphatase Inhibitor (Thermo, Fisher, 
Markham, Ontario) prior to use. Cells were scraped, sheared using 26 gauge needles, and 
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centrifuged at 14,000 × g for 20 min at 4°C. Supernatants were collected, and then frozen at -80°C 
until the point of analysis by immunoblotting (Western blotting). 
2.3.2 Slice preparation  
Male Sprague-Dawley rats were anesthetized with CO2 inhalant and euthanized by decapitation at 
post-natal day (PND) 70. The HP and PFC were immediately extracted from the brain, and slices 
were generated as per standard procedure, then allowed to recover for 90 minutes in artificial 
ACSF that contained (in mM): 127.0 NaCl (Sigma, Oakville, ON, Canada; all subsequent  reagents  
from  Sigma,  unless  otherwise  noted),  26.0  NaHCO3,  10.0  glucose,  2.0 CaCl2,  2.0  KCl,  2.0  
MgSO4,  and  1.2  KH2PO4 and  was  equilibrated  with  carbogen  (95%  O2/5% CO2), pH 7.37–
7.43. After the 90-minute recovery period, slices were transferred to chambers containing the 
respective drugs dissolved to the desired concentration in ACSF. After the treatment period was 
over, slices were homogenized in non-ionizing lysis buffer (containing 10 mM Tris, 25 mM 
ethylenediaminetetraacetic acid [EDTA], 100 mM NaCl, 1% [v/v] Triton X-100, and 1% [v/v] 
NP-40, pH 7.4; protease inhibitor cocktail and sodium orthovanadate added on day of experiment) 
over ice with a Potter-Elvehjem homogenizer, and then centrifuged at 1000 x g for 10 min at 4ºC. 
Supernatants were collected then frozen at -80 ºC until the point of analysis by immunoblotting 
(Western blotting).  
2.3.3 Western blot 
Western blots were performed, and total protein was measured using a BCA protein assay 
(Thermo). Samples were heated in 3x loading buffer (240 mM Tris-HCl at pH 6.8, 6% w/v SDS, 
30% v/v glycerol, 0.02% w/v bromophenol blue, 50 mM DTT, and 5% v/v β-mercaptoethanol) for 
15 min at 75°C and 20-40 μg total protein was loaded into polyacrylamide gel wells. Proteins were 
separated by SDS-PAGE using electrophoresis buffer (25 mM Tris base, 190 mM glycine, 3.5 mM 
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sodium dodecyl sulfate), followed by transfer of proteins to a nitrocellulose membrane by 
electroblotting with transfer buffer (25 mM Tris base, 190 mM glycine, 20% v/v methanol). 
Membranes were then blocked with 5% non-fat milk in Tris-buffered saline (20 mM Tris base, 
150 mM NaCl, pH 7.6) plus 0.1% Tween (TBS-T) for 1 h at room temperature, or overnight at 
4°C, followed by incubation with primary antibody added to blocking buffer for 1 h at room 
temperature, or overnight at 4°C.  Membranes were washed three times with TBS-T, and then 
incubated with a secondary antibody conjugated to horseradish peroxidase (HRP) in blocking 
buffer for 1 h at room temperature. Membranes were washed three additional times with TBS-T. 
Western chemiluminescent substrate (Luminata Crescendo-Millipore) was used to visualize 
proteins on a Kodak 4000MM Pro Imaging Station. Densitometric analyses of images were 
performed using Kodak Molecular Imaging software. After imaging, membranes were stripped 
and re-probed with other appropriate antibodies. Molecular weights of analyzed proteins are as 
follows: PDGFR and PDGF-Y1021 at 180 kDa, TrkB-FL and TrkB-Y816 at 145 kDa and bands 
were normalized to the loading control, β-actin at 42 kDA. Membranes were probed with the 
primary antibodies against, TrkB (Millipore; 1:1000 (rabbit)), pTrk816 (Millipore; 1:500 (rabbit)), 
PDGFRβ (Santa Cruz; 1:1000(rabbit)), PDGFRβ-Y1021 (Santa Cruz; 1:1000(rabbit)), β-actin 
(Santa Cruz; 1:1000 (mouse)). Anti-mouse (1:10000) and anti-rabbit (1:5000) horseradish 
peroxidase (HRP) enzyme-conjugated IgG secondary antibodies were used.  
2.3.4 Statistics 
Given our sample size, a conservative approach was taken regarding the assumptions that could 
be made around normality; as a result, our data were analyzed using non-parametric statistical 
analyses in GraphPad PrismTM 6. Specifically, the Wilcoxon Signed Rank Test (the distribution 
free equivalent of the 1-sample t-test) was used for analyses. TrkB and PDGFβ receptor 
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transactivation data were presented as fold change in receptor phosphorylation (TrkB at 
phosphorylation site Y816 and PDGF at phosphorylation site Y1021) relative to control. The 
respective cumulative fold changes were statistically analyzed using the Wilcoxon signed rank 
test. All error bars represent the standard error of the mean. Additionally, any inter-group 
comparisons were conducted using the Mann-Whitney U Test (the distribution-free equivalent of 
the 2 sample Student’s t-test) and the Bonferroni calculation was applied to protect against the type 
I error. The Bonferroni calculation includes adjusting the alpha value by dividing the original α 
value by the number of groups being compared “n”. The Cohen’s d, effect size calculation that 
measures the standardized difference between two means was used to determine the biological 
relevance of the data. The general formula for Cohen’s d calculation is d= (M1-M2)/S pooled; 
where M1 and M2 represent the means of the two groups being compared and S pooled, represents 
the pooled standard deviation for the two groups. Cohen’s d calculations were completed using an 
online calculator [261]. Cohen’s d conventional values for a small effect size (d = 0.2), a moderate 
effect size (d = 0.5), and a large effect size (d = 0.8) were used for interpreting the data. Outliers 
were identified and removed from the data set using Tukey’s method. Tukey's method was chosen 
since it is a non-parametric method, thus aligning with the general statistical approach of this 
chapter. With Tukey’s method, the outlier value is compared with computed upper and lower 
limits, which are referred to as “fences” for exclusion. Determination of the fences involves 
calculating the interquartile range (IQR), which  is the  difference between the upper  quartile  
(75th  percentile)  and  the  lower  quartile  (25th percentile), for the dataset. The lower fence is 
obtained by subtracting 1.5 times the IQR from the 25th percentile and the upper fence is obtained 
by adding 1.5 times the IQR to the 75th percentile. Any values that fall outside of the calculated 
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range are outliers and can be removed from the dataset [262]. Additionally, any data that were 
subject to experimental error were also excluded. 
 Threshold p values are arbitrary, but are used as probabilities or estimates to determine 
whether the null hypothesis can be rejected. Typical p values range from 0.01 (more 
stringent), 0.05 (standard) and 0.10 (less stringent) [263]. Practical factors (e.g., cost, study time-
line) limited the number animals that were used for this study, which, in conjunction with the 
sensitivity of the readouts, resulted in the selection of a less stringent p value threshold, α = 0.1. In 
addition to p values, effect size calculations were also provided a means to determine the potential 
biological relevance of the given outcomes. Additionally, effect size calculations served as a viable 
secondary measure to determine the acceptance, or rejection of the null hypothesis. 
2.3.5 Data overview 
In order to determine transactivation (the fold change in phosphorylation relative to control), 
control and treatment samples were compared. Specifically, treatment data was divided by the 
control data to establish the fold change. The Western blot procedure is a semi-quantitative 
measure, which yields arbitrary densitometry values that correlate to the intensity of a given band, 
and therefore the relative abundance of a given protein. In this thesis, all control values appear as 
1, as they are the baseline upon which a fold change is evaluated. Generally, the fold change in 
phosphorylation observed in transactivation is fairly modest on averaging ranging from 1.3 to 
about a 3 fold increase relative to control [81, 82]. 
2.4 Results 
We have described transactivation as either acute (observed at a time-point shorter than 60 min), 
or chronic (observed at a time-point greater than 60 min). Importantly, transactivation is a transient 
phenomenon, meaning that, at a given time after drug application, signal (RTK phosphorylation) 
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increases from baseline, escalates to a peak, and then returns back to baseline, as the tyrosine is 
dephosphorylated. Therefore, the timing of the readout is important, as it is possible to miss the 
phenomenon entirely if an observation point is too soon, or too late. For example, in SH-SY5Y 
cells, peak phosphorylation for the PDGFβ receptor is observed at 5 min and returns to baseline 
by 15 min, whilst TrkB phosphorylation is observed at 2 h [56, 81]. Given these factors, a challenge 
associated with characterizing transactivation is determining the appropriate agonist concentration 
and treatment time that would enable one to capture the phenomenon near its peak. As a result, 
our characterization experiments were conducted at various agonist concentrations and treatment 
times. The two RTKs that we chose to evaluate transactivation were the PDGFβ and TrkB 
receptors, at the PDGFβ-Y1021 and TrkB-Y816 sites respectively, as these have been used 
previously as a proxy for RTK activation [56, 76, 82]. The Table below summarises a set of 














2.4.1 Ex vivo slice studies 
 










5-HT 5-HT receptors HP  100 nM  5 PDGF-
Y1021 
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 Table 3. A summary of outcomes of transactivation characterization experiments conducted in ex 
vivo slices.  Please note    = increase   = decrease and “=” equals no notable change in 




The preliminary data (Table 3) reflect that transactivation outcomes differ based on GPCR 
agonist and treatment time. We observed the following: 
2.4.1.1 5-HT receptor activation (treatment: 5HT, LP12, 8-OH-DPAT)  
Acute, 5 min treatment with 100 nM and 100 µM 5-HT in hippocampus ex vivo slices did not 
induce a notable change in PDGF-Y1021 receptor phosphorylation (transactivation). A longer 
treatment (1 h) showed a trend towards increased PDGF-Y1021 phosphorylation, but there was 
considerable variability in this outcome. We observed that the acute treatment of hippocampal 
slices with LP12 for 45 min increased PDGF-Y1021 phosphorylation, additionally, the low p value 
and high d value (p = 0.06, d = 1.77) suggest an effect of treatment. The treatment of hippocampal 
slices with 8-OH-DPAT for 5 min, 15 min and 60 min showed a trend towards an increase in TrkB-
Y816 phosphorylation and this trend increased with treatment time. However, there was no 
statistical significance likely due to the variability in the data. The same treatment was conducted 
in PFC, and at 5 min and 60 min, we observed a trend towards an increase in TrkB-Y816 
phosphorylation, whilst at 15 min the trend suggested a relative decrease in TrkB-Y816 
phosphorylation. However, these outcomes were not statistically significant. 
2.4.1.2 Dopamine receptor activation 
Hippocampal treatment with quinpirole for 10 min resulted in PDGF transactivation and these 
findings were statistically significant. The findings with quinpirole for 45 min, showed a slight 
trend towards an increase in PDGF-Y1021 phosphorylation, but there was no significant 
difference. Given that a significant increase in PDGF-Y1021 phosphorylation was observed after 
a 45 min LP12 treatment and after a 10 min quinpirole treatment respectively, I sought to explore 
if the combined treatment would be additive and synergistic, and what I observed was neither; in 
fact, there was not much change. Additionally, I sought to explore the effect of a combined 
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treatment of quinpirole 10 min and 5-HT for 5 min and what I observed was a greater fold change 
than LP12+ quinpirole, but the difference was not statistically significant.  
In summary, the findings show that LP12 (45 min) and quinpirole (10 min) transactivate 
ex vivo tissue in a statistically significant manner. The trends observed with the combined 
treatments suggest that the combined treatment have higher activation than individual treatments 
alone, but these outcomes were not additive or synergistic. The following sections highlight the 



















2.4.2. 5-HT7 activation of TrkB, Src, Erk 
Based on preliminary studies, ex vivo HP and PFC slices were treated with 300 nM LP12 for 2 h. 
We blotted for TrkB and pTrkB, Src and pSrc, Erk and pErk to evaluate the impact of the 
treatment on the phosphorylation (activation) of these proteins.  
 
                 
 
 
Figure 4. A) HP and B) PFC slices were treated with 300 nM LP12 for 2 h. Following treatment, 
the slices were homogenized and samples evaluated by Western blots as described in the methods. 
The pTrkB data were normalized to total TrkB expression and are expressed as the fold change in 
phospho-816 immunoreactivity (* = p < 0.1; Wilcoxon Signed Rank Test compared to non-treated 
control. LP12-HP: n = 6, p = 0.063, d = 0.99; LP12-PFC: n = 6, p = 0.44, d = 0.66)  
Our findings suggest that LP12 induces transactivation in the HP slices (p = 0.063, d = 
0.99), but not in the PFC slices (p = 0.44, d = 0.66); these data highlight a regional difference in 





















Figure 5. A) HP and B) PFC slices were treated with 300 nM LP12 for 2 h. Following treatment, 
the slices were homogenized and samples evaluated by Western blots as described in the methods. 
The phospho-Src data were normalized to total Src expression and are expressed as the fold change 
in phospho-Src immunoreactivity (Wilcoxon Signed Rank Test compared to non-treated control. 
Src-HP: n = 5, p = 0.31, d = 1.08; Src-PFC: n = 5, p = 0.19, d = 1.20)  
Our findings suggest that LP12 treatment leads to an increase in Src phosphorylation in 
both the HP (p = 0.31, d = 1.08) and the PFC (p = 0.19, d = 1.20) slices. Although these data did 
not reach the threshold for statistical significance, both the HP and PFC displayed large effect 












Figure 6. A) HP and B) PFC slices were treated with 300 nM LP12 for 2 h. Following treatment, 
the slices were homogenised and the samples were evaluated by Western blots as described in the 
methods. The phospho-Erk data were normalized to total Erk 1/2 expression and are expressed as 
the fold change in phospho-Erk immunoreactivity (Wilcoxon Signed Rank Test) compared to non-
treated control. Erk-HP: n = 3, p = 0.25, d = 1.52; Erk-PFC: n = 4, p = 0.88, d = 0.27) 
Our findings suggest that LP12 treatment leads to an increase in Erk phosphorylation in 
the HP (p = 0.25, d = 1.52) but not the PFC (p = 0.88, d = 0.27). Additionally, the effect size is 
very large in the HP, but small in the PFC, suggesting that these outcomes may have a biological 









2.4.5. Corticosterone activation of TrkB   
To evaluate the impact of CORT on TrkB, Src and Erk phosphorylation (activation), ex vivo brain 





Figure 7. A) HP and B) PFC slices were treated with 300nM CORT for 1 hour. Following 
treatment, the slices were lysed and lysates were evaluated by western blots as described in 
methods. Data were normalized to total TrkB expression and are expressed as the fold change in 
phospho- 816 immunoreactivity (*= p< 0.1 (Wilcoxon Signed Rank Test) compared to non-treated 
control, LP12- HP: n = 6, p = 0.094, d = 1.03; LP12-PFC: n = 6, p = 0.16, d = 0.87) 
Our findings suggest that CORT increases TrkB-Y816 phosphorylation in both the HP (p 
= 0.094, d = 1.03) and PFC (p = 0.16, d = 0.87). Even though the outcome is only statistically 
significant in the HP, both regions have large effect sizes, suggesting the biological relevance of 








Figure 8. A) HP and B) PFC slices were treated with 300nM CORT for 1 h. Following treatment, 
the slices were lysed and lysates were evaluated by western blots as described in methods. Data 
were normalized to total Src expression and are expressed as the fold change in phospho- Src 
immunoreactivity. (*=p< 0.1 (Wilcoxon Signed Rank Test) compared to non-treated control, Src- 
HP: n = 5, p = 0.063, d = 1.21; Src-PFC n = 5, p = 0.13, d = 1.15) 
Our findings suggest that corticosterone increases Src phosphorylation. Though the 
findings are only statistically significant in the HP (p = 0.063, d = 1.21) and not the PFC (p= 0.13, 
d= 1.15),  the p value for the PFC, is close to the threshold for statistical significance and both the 
HP and PFC exhibit large effect sizes, suggesting that CORT causes a biologically relevant change 












Figure 9. A) HP and B) PFC slices were treated with 300nM CORT for 1 h. Following treatment, 
the slices were lysed and lysates were evaluated by western blots as described in methods. Data 
were normalized to total TrkB expression and are expressed as the fold change in phospho-816 
immunoreactivity. (*=p< 0.1 (Wilcoxon Signed Rank Test) compared to non-treated control, Erk-
HP: n = 3, p = 0.25, d = 1.34; ERK-PFC: n = 4, p = 0.13, d = 2.78).  
Our findings show that corticosterone may increase Erk phosphorylation, though the 
outcomes are not statistically significant, the combination of relatively low p values and very high 
d values in the HP (p = 0.25, d = 1.34) and PFC (p = 0.13, d = 2.78), suggest that these outcomes 








2.4.6. Combined- CORT+LP12 activation of TrkB 
 To evaluate the impact of a combined CORT and LP12 treatment on TrkB, Src and Erk 
phosphorylation (activation), ex vivo brain slices were treated with 300 nM LP12 for 2 h, then after 






Figure 10. A) HP slices and B) PFC slices were treated with 300nM LP12 treatment for 2 hours 
followed by 300 nM CORT for 1 h. Following treatment, the slices were homogenised and the 
samples were evaluated by Western blots as described in the methods. The phospho-TrkB data 
were normalized to total TrkB expression and are expressed as the fold change in phospho-816 
immunoreactivity. (* = p < 0.1, ** = p < 0.05; (Wilcoxon Signed Rank Test compared to non-
treated control) CORT+LP12 HP: n = 3, p = 0.063, d = 1.19, CORT+LP12 PFC: n = 4, p = 0.03, 
d = 1.75.  
These findings suggest that the combined CORT+LP12 treatment increases TrkB-Y816 





0.063, d = 1.19) and the PFC (p = 0.03, d = 1.75), and the effect sizes, are large in both regions, 
suggesting the biological relevance of these results.    









Figure 11. A) HP slices and B) PFC slices were treated with 300 nM LP12 for 2 h, then 300nM 
CORT for 1 h. Following treatment, the slices were homogenized and the samples were evaluated 
by Western blots as described in the methods. The phospo-Src data were normalized to total Src 
expression and are expressed as the fold change in phospho-Src immunoreactivity. (* = p < 0.1; 
Wilcoxon Signed Rank Test compared to non-treated control). CORT+LP12 Src HP: n = 5, p = 
0.63, d = 0.61; CORT+LP12 Src PFC: n = 5, p = 0.063, d = 1.74). 
These findings suggest that the combined treatment of CORT+LP12 increases Src 
phosphorylation relative to baseline to a significant degree in the PFC (p= 0.063, d= 1.74), but not 








Figure 12. A) HP slices and B) PFC slices were treated with 300nM LP12 for 2 hours then 300nM 
CORT for 1 hour. Following treatment, the slices were lysed and lysates were evaluated by western 
blots as described in methods. Data were normalized to total TrkB expression and are expressed 
as the fold change in phospho- 816 immunoreactivity. (Wilcoxon Signed Rank Test) compared to 
non-treated control, CORT+LP 12 HP: n = 3, p = 0.5000, d = 0.74917; CORT+LP12 PFC: n = 
4, p = 0.8750, d = 0.12340). 
These findings suggest that the combined treatment of CORT+LP12 does not increase Erk 










2.4.7. Comparison of independent and combined treatments    
We sought to evaluate if the combined CORT+LP12 treatment would exhibit additive or 
synergistic effects. Table 2 below shows a comparison (Mann-Whitney) of the LP12 OR CORT 
vs.  CORT + LP12 treatments, to determine if there are significant differences between these 
conditions.  
The statistical analyses below mainly show no difference between the independent and 
combined treatments, suggesting that there are neither additive nor synergistic effects at play.  
Activation Region Comparisons Mann-Whitney  
p values 
TrkB-Y816 HP LP12 vs. CORT+ LP12 0.79 
 PFC LP12 vs. CORT+ LP12 0.026 * 
 HP CORT vs. CORT+LP12 0.57 
 
 PFC CORT vs. CORT+LP12 0.57 
Src HP LP12 vs. CORT+LP12 0.53 
 PFC LP12 vs. CORT+LP12 0.80 
 HP CORT vs. CORT+LP12 0.67 
 PFC CORT vs. CORT+LP12 0.67 
Erk HP LP12 vs. CORT+LP12 0.90 
 PFC LP12 vs. CORT+LP12 0.66 
 HP CORT vs. CORT+LP12 0.90 
 PFC CORT vs. CORT+LP12 0.34 
Table 4. A comparison of independent and combined treatments. * signifies a statistically 




2.4.8 HT22 DATA  
In addition to ex vivo slice work, studies were also conducted in HT22 cells; my goal was to 
characterize the transactivation profile in this new cell line. Given the complexity of characterizing 
transactivation in cell lines (establishing the effective time-frame and drug concentration), a 
conservative approach was chosen wherein I decided to study two receptors that were previously 
successful in activating transactivation in SH-SY5Y cells. Specifically, we studied 5HT1A 
receptors (activated by 8-OH-DPAT) and dopamine 2/3 receptors (activated by quinpirole); 
additionally, the concentrations chosen were based on previous SH-SY5Y work.  
  
Figure 13. HT-22 cells were treated with 10 nM 8-OH-DPAT for the given times. Following 
treatment, the lysates were evaluated by Western blots as described in the methods. Data were 
normalized to total TrkB expression and are expressed as the fold change in phospho- 816 
immunoreactivity. (8-OH-DPAT: 5 min: n = 6, p = 0.22, d = 0.75 ; 15 min: n = 6, p = 0.31, d = 
0.75; 30 min: n = 5, p = 0.13 d = 1.25 ; 45 min: n = 5, p = 0.81 ,d = 0.085; 1 h: n = 6, p = 0.56, d= 
0.43 ; 2 h: n = 9, p= 0.82, d = 0.35; 3 h: n = 6,p = 0.16, d = 1.05 ; 4 h: n = 3, p = 1.00, d = 0.22 ; 6 
h: n = 3,p = 0.75, d = 0.39 ; 12 h: n = 3,p = 0.75, d= 0.34).  
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These data suggest that TrkB transactivation peaks at 3 h, but is relatively high at 5 min 
and 15 min. Though these data display great variability, they still point to the possibility that TrkB-
Y816 can be transactivated by 5-HT1A/ 5-HT7 receptors in HT-22 cells. LP12 data (not shown) 
suggest that 5-HT7 can also activate TrkB receptors in HT-22 cells, however, the data display 
great variability making it difficult to define the exact outcome. Quinpirole data (below) reflect 
that 2 h, 3 h, 4 h and 6 h are the peak of TrkB-Y816 transactivation. These outcomes were 
statistically significant at the 2 h time point (p = 0.03, d = 1.22).  
  
Figure 14. HT22 cells were treated with 10 µM quinpirole at given times. Following treatment, 
the lysates were evaluated by western blots as described in methods. Data were normalized to total 
TrkB expression and are expressed as the fold change in phospho-816 immunoreactivity. (* = p < 
0.1, ** = p < 0.05; (Wilcoxon Signed Rank Test compared to non- treated control); quinpirole: 5 
min: n = 2 , d = 0.11; 15 min: n = 2, d = 1.55; 30 min: n = 2, d = 0.35; 45 min: n = 2, d = 3.13; 1 
h: n = 3, p = 0.25 , d = 1.65; 2 h: n = 6, p = 0.03, d= 1.22; 3 h: n = 3, p = 0.25, d = 3.18; 4 h: n = 
4 , p = 0.13, d = 2.33; 6 h: n = 4, p =0.25 , d = 1.39; 12 h: n = 4, p = 0.63 , d = 0.37).        
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The peaks observed with 8-OH-DPAT (5 min, 15 min and 3 h) and quinpirole (3 h, 4 h and 
6 h) reflect the time-points that require focus when further trying to characterize transactivation. 
The 2 h quinpirole treatment, shows that transactivation can be significantly observed in the HT22 
cells, suggesting that further characterization (increase in sample size etc.) could lead to better 
outcomes at the observed peak times. Unfortunately, the timeline that would be required to fully 
characterize the HT22 cell line, as well as the clear data observed in slice, led to a switch in focus 
from HT-22 cells to ex vivo slice. However, future directions of this project will continue to explore 
transactivation in HT-22 cells.   
2.5.0. Discussion 
One of the aims of this chapter was to replicate transactivation in the ex vivo slice reliably, and this 
aim was achieved through testing various GPCR agonists at various concentrations and treatment 
times to determine the agonist providing the most reliable transactivation outcomes.  Additionally, 
we sought to carry out a preliminary evaluation of transactivation in the HT-22 cell line. Lastly, 
we explored the impact of corticosterone (CORT) treatment, as well as a combined corticosterone 
and LP12 (CORT+LP12) treatment on slices as a means to evaluate the impact of the 
pharmacological stressor on TrkB-Y816 phosphorylation and to see how transactivation may be 
affected by stress.  
Some of the preliminary data (not shown) exhibited greater variability than the later data. 
The preliminary data were generated using a relatively crude protocol in which brain slices were 
prepared manually. Given the variability in that data, steps were taken to refine our protocol to 
enable us to increase slice viability and increase the replicability of our data. Improving the 
protocol included the use of a McIlwain slicer to produce an exact and consistent thickness of 
slices instead of approximating brain slice thickness when manually cutting the slices. 
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Additionally, the increased precision enabled us to more clearly define an origin, or starting point, 
with every slice, which increased the consistency of tissue used across replicates. The refined 
protocol also included using interface perfusion chambers, rather than the submersion method, 
ultimately allowing for greater temperature and humidity control and arguably increased slice 
viability. However, when comparing the outcomes between the crude and refined protocols, we 
found that there was no difference in the magnitude of transactivation observed (the range 
remained between approximately1.3-3), however, we were able to decrease variability and 
replicate transactivation reliably. The increased reliability is likely due to the fact that with the 
refined protocol I was able to more accurately define the regions of study instead of crudely 
generating slices, and I was able to use the exact defined regions of the hippocampus and prefrontal 
cortex each time; additionally, we were able to control for slice thickness. Given the varying 
functions and receptor distribution along the axes of the HP and PFC, the ability to use specific 
regions enabled us to eliminate the inconsistent findings of the previous protocol.  
We were successful in achieving our goal of replicating transactivation in ex vivo slices, as 
well as identifying transactivation in HT-22 cells. Interestingly, comparing the LP12 and CORT 
profiles of TrkB-Y816 activation, it is evident that they share a similar profile; both increase 
activation of TrkB-Y816 relative to baseline. Studies have shown that corticosterone activates an 
unknown GPCR whose activation leads to the activation of multiple secondary messengers like 
PLC, PKA and Phosphoinositide (PI3K) [98]. Further, the activation of these secondary 
messengers leads to the activation of the GluN2B subunit of the NMDA receptor, non-receptor 
tyrosine kinases, like Src, as well as the activation of the protective MAPK pathway [98]. 
Additionally, these secondary messengers have been shown to play a role in the activation of 
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RTKs, and some of these mechanisms include the activation of Src; therefore, these findings 
provide a potential mechanism through which CORT could activate TrkB.  
In addition to addressing how CORT could activate TrkB, it is equally as important to 
consider why. For example, TrkB activation could be a protective mechanism. The line of 
reasoning that a stress hormone activates TrkB-Y816 in a similar fashion as LP12 transactivation, 
the latter being known to have neuroprotective potential, lends to the question: could 
transactivation be an adaptive stress response? Though this is an intriguing consideration, the data 
in this chapter cannot address this question. Given that various stressors have themselves been 
shown to trigger transactivation [110, 111], a future direction of this research would be to directly 
explore the stress-transactivation connection to determine if transactivation is indeed a stress 
response. The outcomes of such work would be significant, and would point towards the 
physiological relevance of transactivation, which is currently not known.  
To explore any additive, or synergistic effects, CORT+LP12 treatments were conducted. 
Concerning TrkB-Y816 phosphorylation, we found that CORT+LP12 did not significantly 
increase TrkB-Y816 phosphorylation compared to CORT alone, or LP12 alone, meaning that 
additive, or synergistic effects were not likely. The lack of a combined effect may point to the 
possibility that CORT and LP12 could be activating TrkB through a similar pathway. Another 
alternative explanation is that TrkB-Y816 activation saturates at the level I observed and no further 
phosphorylation is possible. To determine if they are indeed activating in the same pathway, an 
experiment that could be conducted would be to measure activation of elements upstream, and/or 
downstream of transactivation in CORT slices, and indeed, I found that CORT activates Src and 
Erk1/2 in a similar fashion as LP12. To further verify this notion, the entire pathway could be 
tested by exploring CORT’s effect on all the major proteins within the transactivation pathway.  
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Alternatively, one could argue that a greater concentration of LP12 and/or CORT could be required 
to elicit an additive change, or that different pairs of agonists vs. pharmacological stressors could 
elicit this effect. This could be tested simply by escalating the concentrations of one or both 
LP12/CORT in this experiment, or using high throughput screening of various transactivating 
agonist vs. stressors. Though there are many ways to determine the possibility of additivity or 
synergism, the data we have is sufficient to address the basic question we sought to explore.   
Looking at the HT-22 data, it is evident that we can observe different patterns at the various 
times, but statistical significance was only observed with a 2 h quinpirole treatment. Our general 
null findings could mean that transactivation cannot be easily replicated in HT-22 cells, or at least 
replicated reliably, but given the relative ease with which transactivation has been observed in 
other cell lines, this explanation seems unlikely. Instead, different concentrations (higher and lower 
than the ones used) and times (more acute and chronic than the ones used) of the various agonists 
need to be explored; importantly, the peak times observed could be a guide of further studies in 
the characterization process. In addition, transfection of 5-HT7, dopamine and/or TrkB receptors 
could be conducted to increase the sensitivity of this cell line.   
Overall, I was able to achieve the five aims, and replicate transactivation with 300 nM 
LP12 reliably, I was able to demonstrate activation of messenger proteins connected to TrkB (Src 
and Erk), and I was able to show that CORT does indeed activate TrkB-Y816. I was also able to 
show that though the HP and PFC often had similar trends, the outcomes differed in magnitude or 
direction. However, my hypothesis that CORT+LP12 combined treatment would yield additive, 
or synergistic effects was false, as it indeed turns out that they have similar activation levels. Given 
that I was able to reliably replicate transactivation in this study, this permitted me to lay a 
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foundation upon which I expanded in chapter 4 to explore the interconnection between 
transactivation and stress.  
The following section, chapter 3, introduces chronic early life social isolation (CELSI), an 
in-vivo model of stress and primarily focuses on the impact of CELSI on the expression of 



























Social isolation is a method that is often used to understand the behavioral and physiological 
mechanisms that regulate interactions in social mammals. The impact of social isolation in early-
life has significant adverse effects on the brain development and adult behavior of social animals. 
In addition, various studies have indicated a strong correlation between childhood trauma exposure 
and observed negative health outcomes in adulthood. While the exact physiological and molecular 
mechanisms underlying these outcomes have yet to be understood, evidence suggests that chronic 
early life stress alters neurochemistry, at the level of receptor function and neurotransmission. This 
chapter explores the impact of early life stress on the expression of two plasticity related proteins: 
the TrkB and the GluN2B subunit of the NMDA receptor.  
3.1. Introduction 
Chronic stress experienced during critical developmental stages in mammals has been linked to a 
myriad of negative outcomes in adulthood, including behavioral dysfunctions and an increased 
vulnerability to psychiatric illness [264]. A multitude of studies have repeatedly shown a large 
correlation between early life stressors and risk factors for diseases, including coronary artery 
disease, chronic pulmonary disease and cancer [265].  
 In rodent models, social isolation stress induces marked behavioral changes, which show 
signatures of neuropsychiatric disorders observed in humans, such as schizophrenia and depression 
[266]. For example, studies in which rodents were exposed to social isolation reported an increase 
in locomotor activity in response to novel environments. As well, other reports revealed a variety 
of changes, including an increase in responsiveness to psychostimulants, altered sensorimotor 
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gating of the acoustic startle response, and an impairment in pre-pulse inhibition [267, 268, 269, 
270].  
The molecular origins of the behavioral changes observed after isolation stress are 
beginning to be understood. For example, a study examining the pre-frontal cortex (PFC) of male 
Sprague-Dawley rats isolated at post-natal day 20, showed an abnormal expression- upregulation 
and downregulation of immediate early genes, as well as genes that regulate cell differentiation 
and apoptosis [271]. Given the role of the PFC in executive function and its role in social behaviour 
modulation, changes in its circuitry could explain some of the reported behavioural alterations, 
characteristic of the positive symptoms of schizophrenia and/or the anxiety accompanying 
depression [272].  Although the exact mechanisms underlying these social isolation-induced 
changes have not been fully elucidated, there is evidence to suggest that chronic early life stress 
alters brain neurochemistry at the level of receptor expression, and/or function and 
neurotransmission [273].  
3.1.1 CELSI and TrKB/ BDNF 
Of these alterations in brain neurochemistry, CELSI has been reported to decrease BDNF [273]. 
BDNF is a neurotrophic factor that activates the TrkB receptor, and, through TrkB signalling, 
BDNF regulates the proliferation, differentiation and survival of neuronal and non-neuronal cells 
in the CNS. Additionally, BDNF regulates neuronal plasticity, synaptogenesis, spine formation, 
LTP and neuronal excitability, as well as adult neurogenesis [274]. Neurotrophins, like BDNF, 
engage in cross-talk with, and have a significant role in the calibration of, many neurotransmitter 
systems. In fact, the fine-tuned interaction between neurotrophins and neurotransmitter systems 
regulates a homeostatic state, the disruption of which can trigger neuro-degeneration and 
inflammation [273]. Various mechanisms have been proposed to explain the interaction of early 
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life stress with BDNF. Of these proposed mechanisms is one suggested by Daskalakis et al., 
wherein various models of early life stress epigenetically regulates BDNF expression through 
changes in the methylation patterns of BDNF at exon IV. This regulation was reported to be 
biphasic, with lower methylation of exon IV at post-natal day (PND) 21 and increased methylation 
in adolescence to adulthood [275]. 
The neurotrophic factor theory of depression posits that a reduction in neuronal levels of 
neurotrophic factors, like BDNF, contributes to the pathophysiology of depression [276]. In line 
with this theory, BDNF has been shown to have antidepressant properties [277, 278]. In addition, 
we have shown that the activation of 5-HT7 receptors can increase TrkB receptor expression, and 
this observation may partially explain the ability of antidepressants, which prevent 5-HT reuptake, 
to promote TrkB/BDNF signalling [279]. 
Given the fine-tuned connection between receptor and agonist expression, the evident 
impact of chronic stress on BDNF implies that there might also be stress induced changes in TrkB 
expression. To our knowledge, only one publication exists in the literature that explores the impact 
of CELSI on TrkB expression, therefore our findings will allow us to contribute significantly to 
this topic.   
3.1.2. CELSI and NMDA/Glutamate 
Alongside BDNF/TrkB pathways, the NMDA receptor is another major regulator of 
neuroplasticity [280]. The NMDA receptor is an ionotropic glutamate receptor, which is activated 
by the binding of glutamate and glycine. NMDA receptors have a dimorphic role in the CNS, as 
they play a major role in both neuronal function and neuronal death [273]. Normal, or healthy 
NMDA mediated-glutamergic signalling regulates synaptic-formation, function and learning and 
memory; however, excessive glutamergic signalling can contribute to excitotoxicity, which is 
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implicated in a broad range of neuropathologies, including depression, anxiety, epilepsy and 
schizophrenia [281]. Stress-induced changes on NMDA receptors have been studied extensively, 
and this work has highlighted the role of NMDA receptors in the pathophysiology of stress-
induced depression. Studies conducted by Haj-Mirzaian et al., have shown that adolescent rats 
under social isolation stress displayed a depressed-like phenotype in the forced swim test and 
splash test, which was reversed by sub-effective doses of MK-801, an NMDA antagonist [282].   
In addition, social isolation stress in general increases glutamate levels in the brain, which 
may lead to excitotoxicity, thus resulting in various neuropathologies, including depression, 
anxiety, epilepsy and schizophrenia [254]. Given that social isolation stress has some impact on 
glutamate, the possibility exists that there may also be an effect on the expression of NMDA 
receptors. Further, studies have shown that isolation stress up-regulates GluN2B mRNA receptor 
expression in the hippocampus, and increases NMDA binding capacity in the frontal cortex, thus 
increasing NMDA signalling that could lead to excitotoxicity [283, 284]. Further, mice exposed 
to social isolation stress were demonstrated to have an altered response to ketamine, an NMDA 
antagonist, in the PFC, which highlights the ability of stress to affect circuitry in this region; this 
altered response includes a decrease in GABA expression [285]. 
Both TrkB and GluN2B receptors appear to be important regulators of neuroplasticity, and, 
as such, disruptions to their homeostatic states may trigger neuro-degeneration, and various other 
adverse effects. The effects of CELSI on these essential regulators, and the exact mechanisms of 
action these receptors undergo as a result of this CELSI, is an area that has not been extensively 





3.2 Study objectives  
The aim of this study was to explore the impact of chronic early life social isolation (CELSI) on 
the expression of the TrkB and GluN2B receptors in a sex and region specific manner. To achieve 
this aim, the Western blot was used to measure differences in protein expression in the 
hippocampus and prefrontal cortex of male and female rats, respectively. Given the relative lack 
of female CELSI data (including TrkB data and GluN2B data, specifically) the findings of this 
study will be a significant contribution to the literature. 
3.3. Hypotheses 
3.3.1. TrkB/BDNF:  
I hypothesized that CELSI would decrease BDNF protein expression, while increasing TrkB 
receptor expression. BDNF reduction plays a major role in the pathophysiology of depression; 
therefore, it was anticipated that since CELSI is a psychosocial stressor, it would increase the risk 
for depression in the rodents and lead to a decrease in BDNF protein expression. The rationale for 
an expected increase in TrkB expression is two-fold: i) the upregulation of TrkB would be a 
compensatory mechanism to counter the decrease in BDNF, thus providing a means to sustain 
TrkB-signalling, and ii) given the neuroprotective potential of TrkB signalling, increased TrkB 
expression could be a cellular mechanism to increase protective signaling to counter negative 
CELSI effects.   
3.3.2. GluN2B: 
As mentioned, numerous studies have demonstrated that early life stress (ELS), including CELSI, 
results in an increase in glutamate levels [254]. Given that glutamate activates NMDA receptors, 
I hypothesized that GluN2B expression would decrease, as a protective measure to reduce the 
potential for NMDA-mediated glutamate excitotoxicity. 
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3.3.3. Sex and region:  
Various studies have observed that male and female rats differ in their threshold and response to 
stress [286]. While there are many molecular mechanisms that contribute to reported behavioral 
differences, it was hypothesized that stress would affect key neuronal proteins in a sex- specific 
manner; thus, stress would affect TrkB and GluN2B expression differently in male and female 
rats. Simply stated, if there are stress-induced expression differences, it was anticipated that males 
and females would not have an identical trend. Instead, I anticipated that trends would differ by 
sex, either in magnitude, or in direction. 
 Last, I hypothesized that we would observe region specific differences. The HP and PFC 
are uniquely innervated and have different levels of receptor expression in order to support their 
respective functions [260]. As a result, it is anticipated that if stress-induced expression changes 
are observed, these two regions will not present an identical profile, but will differ either in 
direction, or in magnitude.  
3.4. Materials and Methods  
3.4.1. Biological Assays 
The findings in this chapter represent two cohorts. On post-natal day 21, male and female Sprague-
Dawley rats were randomly separated into the treatment group, or control group and kept within 
that environment for 7 weeks. The rats were housed under a standard 12-hour light/dark cycle at a 
constant room temperature (23°C) and were given ad libitum access to standard rodent chow and 
water. Experiments with animals were carried out in accordance with the guidelines for animal use 
issued by the University of Waterloo Animal Care Committee and according to the protocols 
outlined by the Canadian Council of Animal Care.  
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The rats were anesthetized with CO2 inhalant and euthanized by decapitation at post-natal 
day 70. The hippocampus and prefrontal cortex were immediately extracted from the brain, as per 
standard procedure, and homogenized. Samples were then frozen at -80°C until the point of 
analysis by immunoblotting (Western blotting). Western blots were performed, and total protein 
was measured using a BCA protein assay (Thermo). Samples were heated in 3x loading buffer 
(240 mM Tris-HCl at pH 6.8, 6% w/v SDS, 30% v/v glycerol, 0.02% w/v bromophenol blue, 50 
mM DTT, and 5% v/v β-mercaptoethanol) for 15 min at 75°C and 20-40 μg total protein was 
loaded into polyacrylamide gel wells. Proteins were separated by SDS-PAGE using 
electrophoresis buffer (25 mM Tris base, 190 mM glycine, 3.5 mM sodium dodecyl sulfate), 
followed by transfer of proteins to a nitrocellulose membrane by electroblotting with transfer 
buffer (25 mM Tris base, 190 mM glycine, 20% v/v methanol). Membranes were then blocked 
with 5% non-fat milk in Tris-buffered saline (20 mM Tris base, 150 mM NaCl, pH 7.6) plus 0.1% 
Tween (TBS-T) for 1 h at room temperature, or overnight at 4°C, followed by incubation with 
primary antibody added to blocking buffer for 1 h at room temperature, or overnight at 4°C. 
Membranes were washed three times with TBS-T, and then incubated with a secondary antibody 
conjugated to horse radish peroxidase (HRP) in blocking buffer for 1 h at room temperature. 
Membranes were washed three additional times with TBS-T. Western chemiluminescent substrate 
(Luminata Crescendo-Millipore) was used to visualize proteins on a Kodak 4000MM Pro Imaging 
Station. The images used for analyses were taken from the linear range of exposures. Densitometric 
analyses of images were performed using Kodak Molecular Imaging software. After imaging, 
membranes were stripped and re-probed with other appropriate antibodies. Molecular weights of 
analyzed proteins are as follows: TrkB, 145 kDa; GluN2B, 180 kDa; β-actin, 43 kDa.  Membranes 
were probed with primary antibodies against GluN2B (Millipore; 1:1000), TrkB (Millipore; 
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1:1000), pTrkB-816 (Millipore; 1:500), β-actin (Santa Cruz; 1:1000). Anti-mouse (1:10000) and 
anti-rabbit (1:5000) horseradish peroxidase (HRP) enzyme-conjugated IgG secondary antibodies 
were used. 
Capillary isoelectric focusing with UV whole column imaging detection (CIEF-UV-
WCID) was used to quantitatively determine the relative amount of BDNF protein in GH and SI 
samples. With CIEF-UV-WCID, separation of proteins occurs inside a 5 cm capillary with a 200 
µm ID. The entire length of the capillary is imaged consecutively, the narrow bone capillary 
provides high resolution and sensitivity. Proteins electro-migrate under the electric field and focus 
at their isoelectric point where the net charge is zero. The voltage is increased from 1-3 KV and 









Figure 15. This schematic highlights the experimental protocol. At post-natal day 21 (PND =21) 
the rats were separated into their specific housing conditions. Group housed rats, were housed 3 
rats per cage and socially isolated rats were housed 1 rat per cage. These housing conditions were 
maintained until PND 70, when these rats were sacrificed. Immediately after sacrifice, the HP and 








3.4.2. Statistics  
Given our sample size, a conservative approach was taken regarding the assumptions that could 
be made around normality; as a result, our data were analyzed using non-parametric statistical 
analyses in GraphPad PrismTM 6. Specifically, the Wilcoxon Signed Rank Test (the distribution 
free equivalent of the 1-sample t-test) and the Mann Whitney U Test (the distribution-free 
equivalent of the 2 sample Student’s t-test) were used for analyses. Although our statistical 
approach is effective in determining the main effects, a major limitation is the inability of our 
chosen analytical strategy to elucidate interactions at play that might have contributed to the 
observed outcomes. Therefore, to address this limitation, in those cases where an interaction was 
suspected (given qualitative assessment of interaction graphs) a two-way ANOVA (which assumes 
that our data are taken from a population with a normal distribution) was also conducted to assess 
interactions between the given independent variables.  
TrkB and GluN2B expression data were presented as the fold change relative to control, 
meaning that HP and PFC data from SI animals were normalized to data from their non-stressed 
(that is, GH), same sex siblings. Given that SI data was normalized to GH data and graphically 
presented as a fold change relative to the GH controls, the GH data became the baseline, in other 
words equals to 1. The respective cumulative fold changes were then statistically analyzed.  
One of the aims of this study was to compare region-specific and sex-specific outcomes, 
so the following comparisons were conducted: (i) same receptor, same sex-region comparison (e.g. 
TrkB female-HP vs. TrKB female-PFC comparison) and (ii) same receptor, same region-sex 
comparison (e.g., TrkB HP-male vs. TrKB HP-female comparison). The Mann Whitney U Test 
was used to statistically analyze these comparisons; to protect against the type I error, the 
Bonferroni correction was applied (an adjusted alpha value was used, which was determined by 
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dividing the original α value by the number of groups being compared n). The Cohen’s d, an effect 
size calculation that measures the standardized difference between two means, was used to assess 
the biological relevance of the data. The general formula for Cohen’s d calculation is d = (M1-
M2)/S pooled; where M1 and M2 represent the means of the two groups being compared and S 
pooled, represents the pooled standard deviation for the two groups. Cohen’s d calculations were 
completed using an online calculator [261]. Cohen’s d conventional values for a small effect size 
(d = 0.2), a moderate effect size (d = 0.5), and a large effect size (d = 0.8) were used for interpreting 
the data. Outliers were identified and removed from the data set using Tukey’s method. Tukey's 
method was chosen since it is a non-parametric method, thus aligning with the general statistical 
approach of this thesis. With Tukey’s method, the outlier value is compared with computed upper 
and lower limits, which are referred to as “fences” for exclusion. Determination of the fences 
involves calculating the interquartile range (IQR), which is the difference between the upper 
quartile (75th percentile) and the lower quartile (25th percentile), for the dataset. The lower fence 
is obtained by subtracting 1.5 times the IQR from the 25th percentile and the upper fence is 
obtained by adding 1.5 times the IQR to the 75th percentile. Any values that fell outside of the 
calculated range were regarded as outliers and removed from the dataset [262]. Additionally, any 
data that were subject to experimental error were also excluded.  
The chosen threshold p value was 0.1. In addition to p values, effect size calculations were 
also provided a means to determine the biological relevance of the given outcomes, and served as 






3.5. Results  
3.5.1. GluN2B 
This section describes the impact of CELSI on GluN2B expression in male and female Sprague-
Dawley rats. In male rats we observed no statistically significant difference, but a trend towards 
an increase in GluN2B expression that is more notable in the HP (p = 0.11, d = 0.84) than the PFC 
(p = 0.58, d = 0.58). In females we observed a statistically significant decrease in GluN2B 
expression in the HP (p = 0.03, d = 1.02) and a trend towards a decrease in the PFC (p = 0.15, d = 
0.55). Separate controls were used for the HP and PFC tissue (as shown in the representative 
images), however, given that the control is defined as the baseline (equal to 1, for both HP and 




Figure 16. HP and PFC slices were obtained from GH (group housed- controls) and SI (socially 
isolated) male Sprague-Dawley rats. The slices were homogenised and the samples were evaluated 
by Western blots as described in the methods. Data were normalized to total β-actin protein 
expression and are expressed as the fold change in GluN2B immunoreactivity. GluN2B-HP n = 











Figure 17. HP and PFC slices were obtained from GH (group housed) and SI (socially isolated) 
female Sprague-Dawley rats. The slices were homogenised and the samples were evaluated by 
Western blotting, as described in methods. Data were normalized to total β-actin protein expression 
and are expressed as the fold change in GluN2B immunoreactivity. (** = p < 0.05 (Wilcoxon 
Signed Rank Test)) compared to GH controls. GluN2B-HP n = 11, p = 0.03, d = 1.02 and GluN2B-
PFC n = 13, p = 0.15, d = 0.55.  
3.5.2. TrkB 
This section describes the impact of CELSI on TrkB expression in male and female Sprague 
Dawley rats. In males, it was observed that TrkB expression was increased significantly (*p < 0.1) 
in the HP (p = 0.08, d = 0.68) and a trend towards an increase was observed in the PFC (p = 0.24, 
d = 0.68). In females, we observed a decrease in TrkB expression in the HP (p = 0.19, d = 0.64) 
and a statistically significant decrease in the PFC (p = 0.05, d = 0.80). The CIEF-UV-WCID trial 







Figure 18. HP and PFC slices were obtained from GH (group housed) and SI (socially isolated) 
male Sprague-Dawley rats. The slices were homogenised and the samples were evaluated by 
Western blotting, as described in methods. Data were normalized to total β-actin protein expression 
and are expressed as the fold change in TrkB immunoreactivity respectively. (* = p <0.1 (Wilcoxon 
Signed Rank Test)) compared to GH controls. TrkB-HP n = 11, p = 0.08, d = 0.68 and TrkB-PFC 
n = 11, p = 0.24, d = 0.68.  
  
 
Figure 19. HP and PFC slices were obtained from GH (group housed-control) and SI (socially 
isolated) female Sprague Dawley rats. The slices were lysed and lysates were evaluated by western 
blots, as described in methods. Data was normalized to total β-actin protein expression and are 
expressed as the fold change in TrkB immunoreactivity. (*=p <0.1, **=p < 0.05 (Wilcoxon Signed 
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Rank Test)) compared to controls. TrKB-HP n=14, p=0.19, d=0.64 and TrkB-PFC n=14, p=0.05, 
d= 0.80.  
 
A            B  
 
Figure 20. CIEF-UV-WCID was used as a trial (n=1), to qualitatively determine relative amounts 
of BDNF in female samples. A comparison of egrams GH (group housed-control) and SI (socially 
isolated) homogenates from the (A) prefrontal cortex and (B) hippocampus respectively. 
3.5.3. Sex and region comparisons 
 
Our findings show that there are no statistically significant differences in region (HP vs. PFC), 
however, there are significant sex differences reflected by the large effect size and small p- values.  
Receptor  Sex Comparison p Values  Effect Size 
(d Values) 
GluN2B Male HP vs. PFC > 0.9999 0.13 
 Female HP vs. PFC 0.64 0.25 
TrkB  Male HP vs. PFC 0.93 0.23 
 Female  HP vs. PFC 0.72 0.05 
 
Table 5. CELSI region comparisons. This table shows the region comparison (HP vs. PFC) within 
the same sex and same receptor. Significance was determined by the Mann-Whitney U Test 





Receptor  Region Comparison p Values  Effect Size 
(d Values) 
GluN2B HP Male vs. Females 0.01 1.29 
 PFC Male vs. Females 0.16 0.80 
TrkB  HP Male vs. Females 0.03 0.93 
 PFC Male vs. Females 0.03 0.93 
 
Table 6. CELSI sex comparisons. This table shows the sex comparison- (males vs. females) within 
the same receptor and region. Significance was determined by the Mann Whitney U Test 
(Bonferroni correction was applied) and Cohen’s d values. 
3.5.4. TrkB sex and region comparisons. 
Our data (Table 5 and 6) reflect that there are no statistically significant differences between HP 
and PFC. However, in alignment with our hypothesis, the outcomes observed for the HP and PFC 
are not identical. For instance, with the female data, significant outcomes are observed in the PFC 
but not the HP and the opposite is observed in the male data.  
When exploring sex differences, it is apparent looking at the large effect size values (d = 
0.93 and d = 0.93), that there is a biologically relevant sex difference, and this is corroborated by 
the relatively small p values. Males had an increase in TrkB expression whilst females had a 
decrease. Overall, my hypothesis for TrkB stands true as, for both region and sex comparisons, we 
observed a difference in magnitude in HP vs. PFC and with regards to sex, a difference in direction. 
Additionally, a two-way ANOVA was conducted to explore if there was an interaction of sex (male 
vs. female) and brain region (HP vs. PFC) in TrkB expression, and the outcomes reflect that there 
was no interaction.  
3.5.5. GluN2B sex and region comparisons.  
Our data (Table 5 and 6) reflect that there was no observed statistically significant difference in 
GluN2B expression between the HP and PFC. However, in alignment with our hypothesis, there 
is a difference, though not statistically significant, between HP and PFC. Concerning direction of 
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effect, there was no pattern, as the HP is higher than PFC in males, but the fold change is very 
similar in females, although the PFC appears slightly greater than the HP.  
When exploring sex differences, there was a statistically significant difference between 
males and females in the HP (p = 0.01 and d = 1.29), and a strong trend towards a difference in the 
PFC (p = 0.16 and d = 0.80). The low p values and the high d values, suggest that these outcomes 
are biologically relevant. Males had an increase in GluN2B expression whilst females had a 
decrease. Overall with GluN2B our hypothesis stands true and for both region and sex 
comparisons, as we observed a difference in magnitude in HP vs. PFC and a difference in direction 
for males vs. females. Additionally, a two-way ANOVA was conducted to explore if there is an 
interaction of sex (male vs. females) and brain region (HP vs. PFC) in GluN2B expression, the 
outcomes reflect that there is no interaction.  
In summary, the data in Table 5 reflects that brain region (HP vs. PFC) is not a critical 
factor when it comes to TrkB or GluN2B expression differences, whereas Table 6 reflects that sex 
plays a significant and biologically relevant role in expression differences, and overall no 
interactions of sex or brain region are observed. 
3.6. Discussion  
 
This study sought to evaluate the impact of early life adversity on the expression of two plasticity 
related proteins, the GluN2B subunit of the NMDA receptor and the TrkB receptor. Our findings 
suggest that CELSI affects GluN2B and TrkB expression in a -sex specific manner. Additionally, 
a small sample trial of CIEF-UV-WCID demonstrated the possibility of BDNF protein changes in 






3.6.1 TrkB/BDNF  
A recent review by Murinova et al. confirms our own observation, that there is only one publication 
(Djouma et al., 2006) that explores the impact of CELSI on TrkB protein expression [287]. In this 
publication, Djouma et al. reported an increase in TrkB expression in the HP; however, different 
outcomes were reported across cortical regions, with a decrease in expression observed in the 
cingulate cortex and the piriform cortex, but an increase in expression found in the retrosplenial 
cortex [288]. These findings suggest that in the cortical regions, changes in TrkB expression are 
region specific. To our knowledge, no study has been published that explores TrkB changes in 
female HP and PFC.  
As indicated previously, we hypothesized that we would observe a decrease in BDNF 
expression and a corresponding increase in TrkB expression, after CELSI. We observed a 
statistically significant increase in TrkB expression in the HP of males, and a trend towards an 
increase in the PFC. In contrast, a decrease in TrkB expression in the HP was observed in females, 
and a statistically significant decrease in the PFC was observed. Thus, the outcomes of the male 
data support our hypothesis, whilst the female data reflect a trend that is opposite to what was 
expected.  
Given the limited CELSI-TrkB data in the literature, we explored CELSI-BDNF studies to 
provide an avenue to glean potential TrkB outcomes. We found that many studies report a CELSI-
induced decrease in BDNF expression in the HP [289-298]. Of the few studies conducted in 
females, no change was reported in both the HP and PFC [290, 299] suggesting that, either, no 
change is observed in BDNF after stress in females, or alternatively, that the sample size is not 
large enough to determine an effect. Nevertheless, the findings from this study contribute to the 
much-needed literature on TrkB female studies.  
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The aforementioned interpretation of our findings begs the question: if an increase in TrkB 
expression in a given region implies an adaptive response to stress, what does a decrease in 
expression mean with regards to resilience to stress? In this regard, a study exploring BDNF and 
TRK gene expression changes, in a cohort of animals exposed to ELS, demonstrated that, within 
the same cohort, some animals exhibited superior performance in behavioral tests (stress resilient), 
whereas other animals had inferior performance (stress susceptible). Furthermore, this study 
demonstrated that animals with superior vs. inferior performance had differing patterns of BDNF 
and TrkB mRNA in key brain regions, including the hippocampus and PFC [231]. This underlies 
the fact that even within a cohort of sibling rodents, genetic variability might be limited, but 
significant enough to cause an array of outcomes.  
To validate the interpretation that an increase in TrkB expression is indeed a 
neuroprotective response to stress, we would need to compare the baseline phosphorylation 
(activation) of the TrkB receptor between control and stressed tissues. Additionally, the expression 
and activation of secondary messengers downstream of TrkB activation could be measured 
because receptor changes do not always fully translate into functional changes. Therefore, to get a 
clearer understanding of this observation, we need to also explore various markers of TrkB 
signalling, for example, AKT, Erk 1/2 or CREB to name a few.   
Given the complex interplay between TrkB/BDNF signalling pathways with 
glucocorticoid, dopaminergic and serotonergic signalling during the developmental phase, ELS 
effects would have to be explored in the context of some of these other systems in order to glean 
a full understanding of the impact of ELS, as the TrkB-BDNF signalling does not function in 
isolation.  Being one of few known studies that explicitly explore the impact of CELSI on TrkB 
expression, our work is valuable and contributes further evidence to the literature to help 
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understand the big picture of ELS effects in this system. Further, to address the above-mentioned 
limitations from this study, a follow-up study was conducted (explained in chapter 4) that explores: 
i) baseline TrkB phosphorylation (activation) in CELSI vs. control tissue and ii) the impact of 
CELSI on a 5HT-TrkB crosstalk specific pathway.  
In addition to studying TrkB expression levels, a small sample CIEF-UV-WCID trial was 
conducted in female samples (n = 1) after repeated failure to obtain clear BDNF data using the 
Western blot technique. (The Western blot difficulties were largely related to antibody detection). 
Due to the limited volume of male samples, CIEF-UV-WCID was only conducted in female 
samples. The outcomes suggest a decrease in BDNF protein levels in both the HP and PFC of 
socially isolated rats relative to their group housed controls. Given the sample size, it is not possible 
to determine the true direction of effect concerning BDNF expression, however, given that this 
measure was sensitive enough to detect some change even in such a sample size, suggests to us 
that some change could be occurring at the level of BDNF protein. This outcome aligns with our 
hypothesis that states that CELSI is a psychosocial stressor that will induce a measure of 
depression in the rats, and reduce BDNF expression. This finding is also supported by the BDNF 
trends that have been heavily studied and reported in male animals. Next steps include determining 
BDNF protein levels in CELSI vs. control animals in a sex and region manner.  
In summary, we observed an opposite trend in males and females, with males having an 
increase in TrkB expression and females having a decrease. We also observed a decrease in BDNF 
in females, but given the limited sample size, more replicates need to be run to determine the true 
direction of effect. Overall, these findings are promising and contribute to the literature on CELSI 




3.6.3. GluN2B  
As mentioned previously, stress modulates NMDA receptor expression and signalling [254]. In 
fact, various markers of stress have been shown to regulate NMDA receptor expression. For 
instance, hormonal changes (androgens and estrogens) and changes in neurotransmitters, like 
dopamine, that are implicated in mood and emotion have been shown to affect NMDA receptor 
expression [300]. As a result, a stressor like CELSI will likely affect NMDA receptor expression, 
since it can induce a depressed phenotype, and activate various stress markers. When exploring 
the timing of the stressor, both acute and chronic stressors have been shown to affect NMDA 
receptor expression [254]. More precisely, ELS has been shown to increase glutamergic signalling, 
specifically the extra-synaptic signalling, which, in the context of GluN2B receptors, is implicated 
in negative, excitotoxic signalling [254]. The negative impact of extra-synaptic signalling is 
largely because it antagonizes the pro-survival signalling of the synaptic receptors, in fact, a major 
shift in the balance of synaptic vs. extrasynaptic NMDA receptors can drive cell death and has 
been implicated in neurodegenerative diseases like Alzheimer’s diseases [254]. 
 My hypothesis suggested that a decrease in GluN2B expression would be observed, as a 
protective measure against excessive NMDA mediated glutamergic signalling. Interestingly, my 
findings suggest that there is a trend towards an increase in GluN2B expression in the HP and PFC 
in males, however it is not statistically significant. In contrast, I observed a statistically significant 
decrease in GluN2B expression in the HP and a trend towards a decrease in the PFC in females. 
Therefore, the female data support our hypothesis, whilst the male data do not match the expected 
outcomes. Specifically, the male HP data includes a p value of the HP (p = 0.11) that is very close 
to the parameters for statistical significance, and the large effect size (d = 0.84) also suggests that 
the effect of this change is significant. However, for the PFC, the effect size is moderate (d = 0.58). 
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To put these findings into context and to explore what could underlie the observed increase 
in males and the decrease in females, a viable interpretation could be that this decrease in GluN2B 
expression in females is a neuroprotective mechanism; in contrast, males could be viewed as 
susceptible to stress induced glutamergic signalling. If males do indeed exhibit susceptibility to 
stress-induced excitotoxicity, that could explain their upregulation of TrkB, which may provide 
protection against glutamate excitotoxicity. 
The NMDA receptor is implicated in dynamic signalling and crosstalk with many 
receptors, therefore one way to improve this study would be to explore the activation of proteins 
directly downstream of NMDA/GluN2B activation or exploring GluN2B in the context of other 
signalling pathways. To address these points, our following study (chapter 4) explores how TrkB 
activation affects GluN2B expression.  
In summary, in males we observed an increase in GluN2B, which is contrary to our 
hypothesis, whilst in the females we observed a decrease in GluN2B expression, which aligns with 
our expectations. To put these findings in context of the bigger picture, further work needs to be 













In chapters 2 and 3, transactivation was successfully replicated in tissue slices, and it was 
demonstrated that CELSI regulates TrkB and GluN2B expression in a sex- and region- specific 
manner. Having identified these expression changes, the next goal was to study the impact of 
CELSI on TrkB signalling. Given that TrkB plays a role in functions like neuronal development 
and survival, the receptor communicates extensively with other receptors through various crosstalk 
mechanisms. As a result, I chose to study if CELSI affects a specific transactivation pathway: 5-
HT7-TrkB transactivation (this pathway was characterized in previous work).   
4.1. Introduction 
TrkB transactivation, like direct activation of TrkB, has neuroprotective potential, but, despite this 
potential, the in vivo role of transactivation has not yet been elucidated [10]. Evidence points to 
the fact that many different stressors, including oxidative stress, UV radiation, and shear stress can 
induce transactivation through unknown mechanisms [302, 303, 304]. Additionally, there is 
evidence of transactivation in various human tissues, like the heart where it is thought to play a 
protective role [305]. Therefore, exploring the connection between stress and transactivation will 
provide more understanding as to the physiological relevance of this pathway.  
The possible transactivation-stress connection inspired the question- is transactivation part 
of the stress response? Although seemingly simple, this question is highly complex and has to be 
addressed using a dynamic approach that considers the myriad of molecular players that would 
need to be identified to fully characterize such a pathway. The aim of this chapter is to provide 
important pieces of the puzzle, which will lay a sturdy foundation upon which future studies 
addressing this complex question can be built.  
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The first step was the establishment of a transactivation model (HT-22 cell line, or ex vivo 
brain slices) that was more physiologically relevant than previous models. Once established, the 
model was used to study the effect of stress upon transactivation. Studying “stress effects” included 
evaluating the impact of a pharmacological stressor (i.e., CORT) on RTK activation, and/or 
expression to see how an acute form of stress affects transactivation, before testing a more chronic 
model in the form of CELSI. The most reliable GPCR-RTK transactivation candidates (5-HT7 and 
TrkB) were identified, and transactivation was replicated reliably with 300 nM LP12. In addition, 
CORT was found to activate TrkB in a manner similar to LP12. The study further demonstrated 
that, while the HP and PFC often had similar trends, the magnitude, or direction of the outcome 
differed. As such, this study provided the foundation needed to expand and explore the 
interconnection between transactivation and stress.  
Following chapter 2, we explored the impact of stress on the expression of two plasticity 
related proteins: the TrkB receptor and the GluN2B subunit of the NMDA receptor. The findings 
suggested that CELSI affects GluN2B and TrkB expression in a sex specific manner. In an attempt 
to build upon these two studies, this chapter will take a direct approach to exploring the impact of 
CELSI on the response to LP12 treatment, CORT treatment and CORT+LP12 treatment. 
Considering the complex interplay between TrkB and GluN2B signalling pathways during the 
developmental phase (e.g., with dopaminergic and serotonergic signalling), we explored the effect 
that early life stress had on these proteins in the context of the transactivation pathway. As such, 
in order to clarify the transactivation-stress connection, this chapter provides an exploration of the 





4.2. Study objectives  
The aim of this study was to explore the impact of CELSI on transactivation, and to explore 
whether this chronic, developmental stressor primes the brain for differential response to agonist 
treatment, by comparing the outcomes of TrkB activation and expression, as well as GluN2B 
expression, on tissue slices treated with LP12, CORT, or CORT+LP12.   
4.2.1. Intra-sex comparisons        
The aim of intra-sex comparisons was to evaluate the impact of the treatment(s) on TrkB activation 
and expression, as well as GluN2B expression within a given sex. Intra-male analyses explored if 
there were differences between group housed (GH) and socially isolated (SI) male outcomes of 
LP12, CORT, and CORT+LP12 treatment. Additionally, HP and PFC differences were explored. 
Prior to this point, all reported ex vivo slice work was conducted in male brain slices. The work 
presented below was our first attempt to replicate transactivation in female brain slices, making 
this study relevant in helping us understand if there are sex-related differences in transactivation 
outcomes. As such, observing the trends in CELSI control (non-stressed) female slices was 
imperative to laying a foundation for our understanding of baseline transactivation in female tissue. 
Additionally, it was also important to compare the female control outcomes to those of male 
control slices (from chapter 2) as this comparison helped us understand baseline transactivation in 
male vs. female tissue. Female intra-sex comparisons, explored if there were differences between 
group housed (GH) and socially isolated (SI) outcomes of LP12, CORT and CORT+LP12 






4.2.2. Inter-sex comparisons 
 The aim of inter-sex comparisons was to compare male and female outcomes in TrkB activation. 
Male vs. female differences in the LP12, CORT and CORT+LP12 activation of TrkB were 
evaluated. Additionally, region specific differences in these outcomes were also considered.  
4.3. Hypotheses  
In line with the study objectives, the following hypotheses were made: 
1. Various studies have observed that male and female animals display differences in their 
response to stress. Based on our preliminary findings, it was expected that stress would 
affect TrkB and GluN2B expression in a sex-specific manner.  
2. Additionally, it was hypothesized that region specific differences in males would be 
observed, (as observed in preliminary findings wherein there was an observable difference 
in the HP and PFC regions). Additionally it was anticipated that these regions would differ 
either in the direction, or in magnitude of transactivation.  
3. Based on the findings of chapter 2, it was anticipated that LP12 transactivation of the TrkB 
receptor would be replicated in male derived non-stressed (control) slices. 
4. Based on literature demonstrating that early-life stress can induce TrkB-Y816 
phosphorylation, it was anticipated that there would be a difference in transactivation 
between socially isolated (stressed) vs. group-housed (control) slices, which would differ 
either in magnitude, or in direction.  
5. It was expected that CORT treatment in socially isolated vs. group-housed animals would 
induce different outcomes, in line with literature suggesting that ELS can modify the stress 
response later on in the lifespan.   
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6. Similarly, in slices from group-housed female animals, it was hypothesised transactivation 
and CORT activation would be observed, as was observed in slices from non-stressed male 
animals. Given that both male and female neural tissue express the same receptors (though 
the relative abundance may differ), hypotheses 3-5 were also applied to female-derived 
tissue.   
4.4. Materials, Methods and Statistics.  
A cohort of 40 rats at age PND 21 was used (20 males and 20 females); within each sex, 10 rats 
were group housed and 10 were socially isolated. At the end of the isolation period (approximately 
PND 70-71), each rat was sacrificed and the HP and PFC were extracted (as described in previous 
chapters). The extracted tissue was subjected to one of three treatments: LP12, CORT, or 
CORT+LP12. Tissue from all three treatments was subjected to Western blotting for TrkB-Y816, 
TrkB and GluN2B proteins (as described in previous chapters). Figure 21 provides an outline of 
the experimental procedure. Please note that the general materials, methods and statistics used for 




Figure 21. This schematic outlines the experimental procedure. HP and PFC tissue was obtained 
from male and female rats that had been group housed, or socially isolated. The tissue was 
subsequently treated with LP12, CORT, or CORT+LP12 and all treatments were blotted with 
TrkB-Y816, TrkB, and GluN2B antibodies.  M = male, F = female, GH = group housed, SI = 
socially isolated, HP = hippocampus, PFC = prefrontal cortex, LP12 = LP12 hydrochloride, 
CORT = corticosterone, 816 = blotted with TrkB-Y816 antibody, TrkB = blotted with TrkB 





4.5. Results  
4.5.1. LP12, CORT and CORT+LP12 activation of the TrkB-Y816 receptor in male rats  
Based on preliminary studies (described in chapter 2), ex vivo HP and PFC slices were treated with 
300 nM LP12 for 2 h, 300 nM CORT for 1 h, or a combined treatment of CORT+ LP12.  
 
Figure 22.  HP and PFC slices were treated with 300 nM LP12 for 2 h. Following treatment, the 
slices were homogenized and samples evaluated by Western blots as described in the methods. 
The pTrkB data were normalized to total TrkB expression and are expressed as the fold change in 
phospho-Y816 immunoreactivity (Wilcoxon Signed Rank Test) compared to non-treated control. 
GH-HP: n = 12, p = 0.15, d = 0.74; GH-PFC: n = 14, p = 0.71, d = 0.26; SI-HP: n = 8, p = 0.15, 
d = 0.81; SI-PFC: n = 8, p = 0.64, d = 0.18. 
The data in Figure 22 suggests that LP12 may induce transactivation in the group housed 
(GH) and socially isolated (SI) – HP tissue; though these findings are not statistically significant, 
the relatively low p values and the high d values (0.74 and 0.81, respectively) indicate that a 
biologically significant effect may be present. Notably, there was no statistically significant change 
in TrkB-Y816 phosphorylation in PFC tissue from either GH, or SI animals, which, together with 
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the low effect sizes, strengthens our ability to conclude that transactivation does not occur in the 
PFC. These outcomes show great similarity to those observed in chapter 2, wherein LP12 was 
found to induce transactivation in the HP, while a significant change was not observed in the PFC. 
Additionally, when considering comparisons within the housing groups, the low p values and high 
d values, shown in Table 7 (TrkB-Y816, LP12 activation), suggest the biological relevance of the 
differences between GH-HP vs. GH-PFC and SI-HP vs. SI-PFC. Conversely, the high p values 
and low d values for the intra-region comparisons suggest that there is no notable difference 
between GH-HP and SI-HP vs GH-PFC and SI-PFC. In summary, the outcomes observed are 
similar in magnitude and direction across the housing conditions (SI and GH), which might suggest 
that brain region, not isolation stress, is a more important factor influencing transactivation in male 
animals. Additionally, a two-way ANOVA was conducted to explore if there is an interaction of 
housing (GH vs. SI) and brain region (HP vs. PFC) in TrkB transactivation, the outcomes reflect 
that there is no interaction. Furthermore, the findings of the ANOVA show that there is a 
statistically significant effect of brain region (p = 0.0209), corroborating the earlier statement that 









Figure 23.  HP and PFC slices were treated with 300 nM CORT for 1 h. Following treatment, the 
slices were homogenized and samples evaluated by Western blots as described in the methods. 
The pTrkB data were normalized to total TrkB expression and are expressed as the fold change in 
phospho-Y816 immunoreactivity (* = p < 0.1; ** = p < 0.05; Wilcoxon Signed Rank Test) 
compared to non-treated control. GH-HP: n = 13, p = 0.50, d = 0.41; GH-PFC: n = 13, p = 0.68, 
d = 0.20; SI-HP: n = 8, p = 0.84, d = 0.42; SI-PFC: n = 8, p = 0.016, d = 1.97. 
The outcomes displayed in Figure 23 suggest that CORT has no effect on TrkB-Y816 
activation in HP tissue from the GH and SI animals. Additionally, a trend towards a decrease in 
TrkB-Y816 phosphorylation was observed in PFC tissue; in particular, this outcome was 
statistically significant (p = 0.016), and had a very large effect size (d = 1.97) in the SI-PFC tissue. 
When taking a closer look at intra-housing comparisons and intra-region comparisons (Table 7), 
the difference in TrkB-Y816 between SI-HP vs. SI-PFC seems to be biologically relevant, whilst 
the GH-HP vs GH-PFC does not; finally, the difference between GH-PFC vs. SI-PFC appears 
relevant, whilst the difference between GH-HP vs. SI-HP does not. Overall, these findings display 
clear region dependent patterns that are observed in both housing conditions, once again pointing 
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to the impact of brain region on these outcomes. Given these outcomes, a two-way ANOVA was 
conducted to explore if there is an interaction of housing (GH vs. SI) and brain region (HP vs. 
PFC); however, the outcomes reflect that there is no interaction. Furthermore, the findings of the 
ANOVA show that there is a statistically significant effect of brain region (p = 0.027), affirming 








Figure 24.  HP and PFC slices were treated with 300 nM LP12 for 2 h, then 300 nM CORT for 1 
h. Following treatment, the slices were homogenized and samples evaluated by Western blots as 
described in the methods. The pTrkB data were normalized to total TrkB expression and are 
expressed as the fold change in phospho-Y816 immunoreactivity (* = p < 0.1; Wilcoxon Signed 
Rank Test) compared to non-treated control. GH-HP: n = 11, p = 0.21, d = 0.61; GH-PFC: n = 
13, p = 0.068, d = 0.84; SI-HP: n = 6, p = 0.44, d = 0.12; SI-PFC: n = 7, p = 0.81, d = 0.14.  
The outcomes displayed in Figure 24 show a statistically significant difference in the GH-
PFC group that is not observed in other groups. Further, the GH-PFC group has both statistical 
significance (p = 0.068) and a large effect size (d = 0.84), while the other conditions reflect high p 
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values and low d values, suggesting that the changes observed in these groups is likely due to some 
combination of chance and error, specifically the SI-HP group which had the greatest variability 
about the mean. When considering intra-housing comparisons and intra-region comparisons, the 
lack of statistical significance, coupled with low-medium effect sizes (Table 7) suggests that these 
trends are likely not biologically relevant.  
In summary, no interactions of brain region and housing were observed. Data show that 
LP12 likely transactivates TrkB-Y816 in HP slices (GH and SI), and that CORT has no effect on 
HP slices (GH and SI) but induces a significant decrease in SI-PFC tissue. These findings suggest 
that: i) LP12 has greater capacity to activate TrkB-Y816 than CORT and ii) TrkB-Y816 activation 
is more likely to be influenced by brain region (HP vs. PFC) than housing condition (GH vs. SI). 
The combined CORT+LP12 treatment shows a significant difference in the GH-PFC tissue; this 
is a key finding, given that separate LP12 and CORT treatments showed a reduction in TrkB-Y816 
activation in the GH-PFC. The unexpected finding implies that CORT+LP12, through some 












 Comparison  p-value  d-value  
TrkB-Y816 activation GH- HP vs. GH-PFC 0.12 0.75 
(LP12 treatment) SI-HP vs. SI-PFC 0.19 0.74 
 GH-HP vs. SI-HP 0.78 0.13 
 GH-PFC vs. SI-PFC 0.91 0.0042 
TrkB-Y816 activation GH-HP vs. GH-PFC 0.47 0.44 
(CORT treatment) SI-HP vs. SI-PFC 0.19 0.86 
 GH-HP vs. SI-HP 0.78 0.21 
 GH-PFC vs. SI-PFC 0.10 0.86 
TrkB-Y816 activation GH-HP vs. GH-PFC 0.68 0.36 
(CORT+LP12  SI-HP vs. SI-PFC 0.52 0.26 
Treatment) GH-HP vs. SI-HP 0.51 0.44 
 GH-PFC vs. SI-PFC 0.73 0.52 
 
Table 7. Region and housing comparisons in male TrkB-Y816 activation. To explore region and 
housing specific differences in TrkB-Y816 activation, the Mann-Whitney U test (α=0.05 








4.5.2. LP12, CORT and CORT+LP12 effect on expression of the TrkB receptor and GluN2B 
subunit in male rats  
Expression data show some changes in male TrkB and GluN2B expression based on LP12, CORT, 
or CORT+LP12 treatment.  
Figure 25. HP and PFC slices from male Sprague-Dawley rats were treated with 300 nM LP12 
for 2 h. Following treatment, the slices were homogenized and the samples were evaluated by 
Western blots as described in the methods. Data were normalized to total β-actin expression and 
are expressed as the fold change in TrkB immunoreactivity (Wilcoxon Signed Rank Test) 
compared to non-treated control.GH-HP: n = 7, p = 0.94, d = 0.30; GH-PFC: n = 8, p = 0.64, d = 
0.28, SI-HP: n = 9, p = 0.50, d = 0.60; SI-PFC: n = 8, p = 0.15, d = 1.045. 
LP12 treatment has no effect on TrkB expression in the GH-HP and GH-PFC tissue; 
however, there is a slight decrease in the SI-HP and SI-PFC, which may be biologically relevant 










Figure 26. HP and PFC slices from male Sprague-Dawley rats were treated with 300 nM CORT 
for 1 h. Following treatment, the slices were homogenised and the samples were evaluated by 
Western blots as described in the methods. Data were normalized to total β-actin expression and 
are expressed as the fold change in TrkB immunoreactivity (Wilcoxon Signed Rank Test) 
compared to non-treated control. GH-HP: n = 8, p = 0.95, d = 0.047; GH-PFC: n = 8, p = 0.84, d 
= 0.35, SI-HP: n = 8, p = 0.38, d = 0.52; SI-PFC: n = 8, p = 0.74, d = 0.20. 
CORT treatment does not seem to have an effect on TrkB expression, suggesting that 
CORT treatment for 1 h may not be generally sufficient to induce changes in receptor expression 





Figure 27. HP and PFC slices from male Sprague-Dawley rats were treated with 300 nM LP12 
for 2 h and then 300 nM CORT for 1 h. Following treatment, the slices were homogenised and the 
samples were evaluated by Western blots as described in the methods. Data were normalized to 
total β-actin expression and are expressed as the fold change in TrkB immunoreactivity (Wilcoxon 
Signed Rank Test) compared to non-treated control. GH-HP: n = 7, p = 0.58, d = 0.20; GH-PFC: 
n = 7, p = 0.11, d = 0.98, SI-HP: n = 8, p = 0.055, d = 1.13; SI-PFC: n = 6, p = 0.031, d = 4.94. 
Most CORT+LP12 data show a general decrease in TrkB expression in both GH and SI 
groups; notably, the decrease is statistically significant in SI regions: SI-HP, (p = 0.055) and SI-
PFC, (p = 0.031). The CORT+LP12 data reflect that, overall, TrkB expression is higher in the HP 
than the PFC in both GH and SI groups, which is corroborated by the low p values and high d 
values in GH and SI: HP vs. PFC comparisons (Table 8) suggesting that these outcomes are 
biologically relevant. A two-way ANOVA was conducted to explore if there was any interaction 
between housing and brain region, and no interaction was observed; however, a statistically 




Figure 28. HP and PFC slices from male Sprague-Dawley rats were treated with 300 nM LP12 
for 2 h. Following treatment, the slices were homogenised and the samples were evaluated by 
Western blots as described in the methods. Data were normalized to total β-actin expression and 
are expressed as the fold change in GluN2B immunoreactivity (Wilcoxon Signed Rank Test) 
compared to non-treated control. GH-HP: n = 6, p = 0.16, d = 1.11; GH-PFC: n = 4, p = 0.36, d 
= 0.96; SI-HP: n = 6, p = 1.00, d = 0.024; SI-PFC: n = 5, p = 0.63, d = 0.46. 
For GluN2B expression, the data suggest that LP12 treatment may have increased 
expression in the GH-HP group (p = 0.16, d = 1.11) and may have caused a decrease in the GH-
PFC (p = 0.36, d = 0.96) group, but no change in either of the SI groups. Though the findings in 
the GH tissue are not statistically significant, the high effect sizes suggest that these data may be 
biologically relevant. Further, region and housing comparisons show a biologically relevant 
difference between GH-HP vs. GH-PFC (d = 1.45) and GH-HP vs. SI-HP (d = 1.05) groups (Table 
8). A two-way ANOVA was conducted- to explore if there is any interaction between housing and 
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brain region, and no interaction was observed; however, a statistically significant effect of brain 
region (p = 0.042) was observed.   
 
Figure 29. HP and PFC slices from male- Sprague-Dawley rats were treated with 300 nM CORT 
for 1 h. Following treatment, the slices were homogenised and the samples were evaluated by 
Western blots as described in the methods. Data were normalized to total β-actin expression and 
are expressed as the fold change in GluN2B immunoreactivity (Wilcoxon Signed Rank Test) 
compared to non-treated control. GH-HP: n = 6, p = 1.00, d = 0.38; GH-PFC: n = 4, p = 0.88, d 
= 0.040; SI-HP: n = 5, p = 0.063, d = 3.54; SI-PFC: n = 5, p = 0.063, d = 1.51. 
The high p values and low d values suggest that CORT treatment had no effect on GluN2B 
expression in the GH groups; however, in the SI groups there was a significant decrease in HP 
expression and a significant increase in PFC expression; SI-HP: p = 0.063 and SI-PFC: p = 0.063. 
Further, region and housing comparisons (Table 8) show a biologically relevant difference 
between SI-HP vs. SI-PFC (d = 2.3) and GH-HP vs. SI-HP (d = 1.02), suggesting region 
differences in the SI group and housing specific differences in the HP, respectively. Further, a two-
way ANOVA was conducted to explore if there was any interaction between housing and brain 
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Figure 30. HP and PFC slices from male Sprague-Dawley rats were treated with 300 nM LP12 
for 2 h and then 300 nM CORT for 1 h. Following treatment, the slices were homogenised and 
samples were evaluated by Western blots as described in methods. Data were normalized to total 
β-actin expression and are expressed as the fold change in TrkB immunoreactivity (*=p< 0.1 
Wilcoxon Signed Rank Test) compared to non-treated control. GH-HP: n = 5, p = 0.63, d = 0.01; 
GH-PFC: n = 3, p = 0.50, d = 0.96, SI-HP: n = 5, p = 0.31, d = 0.74; SI-PFC: n = 3, p = 1.00, d 
= 0.055. 
The CORT+LP12 data suggest that there may be no change in GluN2B expression, except 
for the GH-PFC, in which a possible increase was observed (d = 0.96); however, the GH-PFC 
group also had the smallest sample size of the groups examined.  
In summary, the findings show that LP, CORT and CORT+LP12 can affect TrkB and 
GluN2B expression in male brain slices. Though many of the observed changes appear to be driven 
by brain region, some effects are as a result of the housing condition. For TrkB, CORT+ LP12 
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treatment induces a decrease in TrkB expression in the SI-HP and SI-PFC groups; for GluN2B, 
CORT treatment significantly reduces SI-HP GluN2B expression, but significantly increases SI-
PFC expression. In addition, in the GluN2B data a trend is observed in which individual treatment 
with either LP12, or CORT leads to changes in expression such that GH-HP > SI-HP and GH-PFC 
























Table 8. Region and housing comparisons in male TrkB and GluN2B expression. To explore region and 
housing specific differences in TrkB and GluN2B expression, Mann-Whitney (α = 0.05 (Bonferroni 
correction)) and corresponding effect size calculations were performed. 
 Comparisons  p-value d-value 
TrkB-LP12 GH- HP vs. GH-PFC 0.2785 
 
0.41 
 SI-HP vs. SI- PFC 0.3148 
 
0.45 
 GH- HP vs. SI- HP 0.4643 
 
0.54 
 GH- PFC vs. SI-PFC 0.8541 
 
0.27 
TrkB-CORT GH- HP vs. GH-PFC 0.8541 
 
0.31 
 SI-HP vs. SI- PFC 0.8541 
 
0.07 
 GH- HP vs. SI- HP 0.5604 
 
0.29 
 GH- PFC vs. SI-PFC 0.9319 
 
0.40 




TrkB-CORT+LP12 SI-HP vs. SI- PFC 0.0806 
 
0.97 
 GH- HP vs. SI- HP 0.2303 
 
0.76 
 GH- PFC vs. SI-PFC 0.7005 
 
0.42 
GluN2B-LP12 GH- HP vs. GH-PFC 0.1143 
 
1.45 
 SI-HP vs. SI- PFC 0.6277 
 
0.22 
 GH- HP vs. SI- HP 0.3052 
 
1.05 
 GH- PFC vs. SI-PFC 0.6825 
 
0.69 
GluN2B-CORT GH- HP vs. GH-PFC 0.8286 
 
0.27 
 SI-HP vs. SI- PFC 0.0519 
 
2.33 
 GH- HP vs. SI- HP 0.1255 
 
1.02 
 GH- PFC vs. SI-PFC 0.1905 
 
1.00 
GluN2B-CORT+LP12 GH- HP vs. GH-PFC 0.3593 
 
0.72 
 SI-HP vs. SI- PFC 0.7857 
 
0.40 
 GH- HP vs. SI- HP 0.6667 
 
0.37 





4.5.3. LP12, CORT and CORT+LP12 activation of the TrkB-Y816 receptor in female rats 
Based on preliminary studies, ex vivo HP and PFC slices were treated with 300 nM LP12 for 2 h, 
300 nM CORT for 1 h, or a combined treatment of CORT+LP12.   
Figure 31.  HP and PFC slices were treated with 300 nM LP12 for 2 h, the slices were then 
homogenized, and samples evaluated by Western blots as described in the methods. The pTrkB 
data were normalized to total TrkB expression and are expressed as the fold change in phospho-
Y816 immunoreactivity (Wilcoxon Signed Rank Test) compared to non-treated control. GH-HP: 
n = 9, p = 0.65, d = 0.29; GH-PFC: n = 8, p = 1.00, d = 0.14; SI-HP: n = 8, p = 0.25, d = 0.76; SI-
PFC: n = 8, p = 0.64, d = 0.27. 
 These data show that LP12 may induce transactivation in the SI-HP tissue, the p value 
(0.25) is not statistically significant, but a large effect size (d = 0.79) is observed. The d value 
suggests that treatment leads to an effect that is large enough to have biological relevance, but the 
p value does not allow us to strongly state that the effect is not chance-driven. Additionally, the 
small effect sizes and high p values for the remaining groups (shown in the Figure 31 legend) 
suggest that transactivation is not likely in the other three conditions. Since transactivation 
appeared to be present in the SI-HP group, but not the GH-HP group, this suggests that the HP 
111 
 
(but not the PFC) is sensitive to an isolation- (housing) difference. When considering intra-housing 
comparisons for SI-HP vs. SI-PFC, Table 9 shows a large effect size (d = 0.8). Intra-region 
differences (GH-HP vs. SI-HP) also display a large effect size (d = 0.82), suggesting the biological 
relevance of these outcomes. A two-way ANOVA was conducted to explore if there is any 
interaction between housing and brain region, and no interaction was observed. 
 
Figure 32.  HP and PFC slices were treated with 300 nM CORT for 1 h, the slices were 
homogenized, and samples evaluated by Western blots as described in the methods. The pTrkB 
data were normalized to total TrkB expression and are expressed as the fold change in phospho-
Y816 immunoreactivity (Wilcoxon Signed Rank Test) compared to non-treated control. GH-HP: 
n = 8, p = 0.15, d = 0.77; GH-PFC: n = 8, p = 0.95, d = 0.0088; SI-HP: n = 7, p = 0.38, d = 0.54; 
SI-PFC: n = 6, p = 1.00, d = 0.30.  
These findings suggest that corticosterone may activate TrkB-Y816 in GH-HP tissue, 
however, activation is not observed in the PFC slices. Generally, these data show that there is no 
isolation specific change as both GH and SI slices from within the brain regions have similar 
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outcomes. The data in Table 9 suggest that there are no significant intra-housing or intra-region 
differences in TrkB-Y816 activation as a result of CORT treatment.  
 
 
Figure 33. HP and PFC slices were treated with 300 nM LP12 for 2 h and then CORT for 1 h, the 
slices were homogenized, and samples evaluated by Western blots as described in the methods. 
The pTrkB data were normalized to total TrkB expression and are expressed as the fold change in 
phospho-Y816 immunoreactivity (* = p < 0.1, ** = p < 0.05; Wilcoxon Signed Rank Test) 
compared to non-treated control. GH-HP: n = 9, p = 0.020, d = 1.58; GH-PFC: n = 8, p = 0.95, d 
= 0.15; SI-HP: n = 7, p = 0.22, d = 0.88; SI-PFC: n = 8, p = 0.74, d = 0.26. 
The findings suggest that the combined CORT+LP12 treatment, increases TrkB-Y816 
phosphorylation in GH- HP tissue and this outcome is statistically significant. This treatment may 
also increase SI- HP phosphorylation, however no changes were observed with GH-PFC or SI-
PFC tissue. It is interesting to note that the profile of these data show similarity with those observed 
in figure 32 (female-CORT); the difference in the HP between the GH and SI groups suggests an 
interaction between housing condition and brain region. Whilst all other intra-housing and intra-
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region comparisons show no notable difference in CORT+LP12 induced changes in TrkB-Y816 
activation, the data in Table 9 suggest that the difference between GH-HP and GH-PFC (p = 0.074, 
d = 1.051) is biologically relevant. A two-way ANOVA was conducted to explore if there is any 
interaction between housing and brain region, and no interaction was observed; however, a 
statistically significant effect of brain region was observed (p = 0.0495) 
In summary, in female animals LP12 transactivation may only occur in the SI-HP group, 
and CORT and CORT+LP12 outcomes show a trend in which TrkB-Y816 activation is more 
apparent in the HP, but not the PFC, groups. Interestingly, these outcomes match the finding in the 





 Comparison  p value  d value  
TrkB-Y816 activation GH- HP vs. GH-PFC 0.93 0.23 
(LP12 treatment) SI-HP vs. SI-PFC 0.27 
 
0.80 
 GH-HP vs. SI-HP 0.14 
 
0.82 
 GH-PFC vs. SI-PFC 0.85 0.27 
TrkB-Y816 activation GH-HP vs. GH-PFC 0.43 
 
0.46 
(CORT treatment) SI-HP vs. SI-PFC 0.60 
 
0.24 
 GH-HP vs. SI-HP 0.75 
 
0.11 
 GH-PFC vs. SI-PFC 0.34 
 
0.17 
TrkB-Y816 activation GH-HP vs. GH-PFC 0.074 1.051 
(CORT+LP12 SI-HP vs. SI-PFC 0.46 0.37 
Treatment) GH-HP vs. SI-HP 0.25 
 
0.75 
 GH-PFC vs. SI-PFC 0.70 0.069 
 
Table 9. Region and housing comparisons in female TrkB-Y816 activation. To explore region and 
housing specific differences in TrkB-Y816 activation, the Mann-Whitney U test (α = 0.05; 








4.5.4. LP12, CORT and CORT+LP12 effect on TrkB and Glu2NB in female rats  
Expression data show that there are changes in female TrkB and GluN2B expression based on 




Figure 34. HP and PFC slices from female Sprague-Dawley rats were treated with 300 nM LP12 
for 2 h. Following treatment, the slices were homogenised and the samples were evaluated by 
Western blotting as described in methods. Data were normalized to total β-actin expression and 
are expressed as the fold change in TrkB immunoreactivity (* = p < 0.1, ** = p < 0.05 Wilcoxon 
Signed Rank Test) compared to non-treated control. GH-HP: n = 7, p = 0.38, d = 0.53; GH-PFC: 
n = 8, p = 0.0078, d = 3.75; SI-HP: n = 5, p = 0.19, d = 0.93; SI-PFC: n = 8, p = 0.95, d = 0.014.  
LP12 treatment did not affect TrKB expression in the GH-HP, or SI-HP slices, however a 
40% decrease, was observed in GH-PFC slices (p = 0.0078, d = 3.75) (but was not observed in SI-
PFC slices). Additionally, a significant difference (p = 0.0059 d = 1.58) was observed between 
GH-HP and GH-PFC groups (Table 10), reflecting a region specific difference within the GH 
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slices. Further, the difference observed between GH-PFC and SI-PFC was also significant (p = 






Figure 35. HP and PFC slices from female Sprague-Dawley rats were treated with 300 nM CORT 
for 1 h. Following treatment, the slices were homogenised and the samples were evaluated by 
Western blotting as described in methods. Data were normalized to total β-actin expression and 
are expressed as the fold change in TrkB immunoreactivity (* = p < 0.1 Wilcoxon Signed Rank 
Test) compared to non-treated control. GH-HP: n = 6, p = 0.031, d = 3.10; GH-PFC: n = 9, p = 
0.13, d = 0.90; SI-HP: n = 5, p = 0.63, d = 0.47; SI-PFC: n =8, p = 0.46, d = 0.41. 
CORT treatment does not have an effect on TrkB expression in the SI-HP and SI-PFC 
groups, but may cause a modest decrease in expression (of 10-15%) in the GH-HP group (p = 
0.031, d = 3.10) and a similar decrease is observed in the GH-PFC group. A two-way ANOVA 
was conducted to explore if there was any interaction between housing and brain region, and no 






Figure 36. HP and PFC slices from female Sprague-Dawley rats were treated with 300 nM LP12 
for 2 h followed by 300 nM CORT for 1 h. Following treatment, the slices were homogenised and 
the samples were evaluated by Western blotting as described in methods. Data were normalized to 
total β-actin expression and are expressed as the fold change in TrkB immunoreactivity (* = p < 
0.1, ** = p < 0.05 Wilcoxon Signed Rank Test) compared to non-treated control. GH-HP: n = 7, 
p = 0.38, d = 0.42; GH-PFC: n = 9, p = 0.020, d = 1.29; SI-HP: n = 5, p = 1.00, d = 0.24; SI-PFC: 
n = 7, p = 0.94, d = 0.047. 
CORT+LP12 data show a statistically significant decrease in TrkB expression in the GH-









Figure 37. HP and PFC slices from female Sprague-Dawley rats were treated with 300 nM LP12 
for 2 h. Following treatment, the slices were homogenised and the samples were evaluated by 
Western blotting as described in methods. Data were normalized to total β-actin expression and 
are expressed as the fold change in GluN2B immunoreactivity (Wilcoxon Signed Rank Test) 
compared to non-treated control. GH-HP: n = 6, p = 0.69, d = 0.35; GH-PFC: n = 8, p = 0.55, d 
= 0.053; SI-HP: n = 5, p = 0.31, d = 0.77; SI-PFC: n = 7, p = 0.30, d = 0.87. 
 LP12 treatment causes a modest increase in GluN2B expression, which given the 
relatively low p values and the high d values in the SI-HP and SI-PFC groups, may be biologically 






Figure 38. HP and PFC slices from female Sprague-Dawley rats were treated with 300 nM CORT 
for 1 h. Following treatment, the slices were homogenised and the samples were evaluated by 
Western blotting as described in methods. Data were normalized to total β-actin expression and 
are expressed as the fold change in GluN2B immunoreactivity (Wilcoxon Signed Rank Test) 
compared to non-treated control. GH-HP: n = 6, p = 0.16, d = 1.10; GH-PFC: n = 8 , p = 0.74,  d 
= 0.27; SI-HP: n = 4, p = 0.38, d = 0.91; SI-PFC: n = 7, p = 0.22, d = 0.89. 
Several trends are observed with GluN2B after CORT treatment, with a modest increase 
in expression observed in the SI-HP and SI-PFC groups (d = 0.90 and 0.89, respectively), while 









Figure 39. HP and PFC slices from female Sprague-Dawley rats were treated with 300 nM LP12 
for 2 h and then 300 nM CORT for 1 h. Following treatment, the slices were homogenised and the 
samples were evaluated by Western blotting as described in methods. Data were normalized to 
total β-actin expression and are expressed as the fold change in TrkB immunoreactivity (* = p < 
0.1, Wilcoxon Signed Rank Test) compared to non-treated control. GH-HP: n = 6, p = 0.56, d = 
0.31; GH-PFC: n = 8, p = 0.078, d = 0.94; SI-HP: n = 3, p = 0.50, d = 0.69; SI-PFC: n = 7, p = 
0.078, d = 1.13. 
For CORT+LP12, a statistically significant increase was observed in GluN2B expression 
in the SI-PFC group, while a statistically significant decrease was observed in the GH-PFC group. 
Additionally, the difference observed between GH-PFC vs. SI-PFC was clearly significant (p = 
0.029 and d = 1.44), suggesting a housing specific effect. A two-way ANOVA was conducted to 
explore if there was any interaction between housing and brain region, and no interaction was 
observed; however, a statistically significant effect of housing was observed (p = 0.038). 
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In summary, to varying degrees, LP12, CORT and CORT+LP12 treatments all cause a 
decrease in TrKB expression in the GH-PFC group. Additionally, the changes observed in GluN2B 
expression, suggest a housing specific effect, as there are differences in magnitude and/or direction 
























Table 10. Region and housing comparisons in female TrkB and GluN2B expression. To explore region and 
housing specific differences in TrkB and GluN2B expression, the Mann-Whitney U test (α = 0.05 with 
Bonferroni correction) and corresponding effect size calculations were performed. 
 
 Comparisons  
 
p-value d-value 
TrkB-LP12 GH- HP vs. GH-PFC 0.0059 
 
1.58 
 SI-HP vs. SI- PFC 0.8827 
 
0.28 
 GH- HP vs. SI- HP 0.6313 
 
0.02 
 GH- PFC vs. SI-PFC 0.0499 
 
1.26 
TrkB-CORT GH- HP vs. GH-PFC 0.6549 
 
0.44 
 SI-HP vs. SI- PFC 0.2720 
 
0.57 
 GH- HP vs. SI- HP 0.0823 
 
1.33 
 GH- PFC vs. SI-PFC 0.1135 
 
0.84 
 GH- HP vs. GH-PFC 0.7292 
 
0.24 
TrkB-CORT+LP12 SI-HP vs. SI- PFC 0.9369 
 
0.11 
 GH- HP vs. SI- HP 0.4293 
 
0.21 
 GH- PFC vs. SI-PFC 0.2509 
 
0.62 
GluN2B-LP12 GH- HP vs. GH-PFC 0.3430 
 
0.24 
 SI-HP vs. SI- PFC 0.7096 
 
0.09 
 GH- HP vs. SI- HP 0.7706 
 
0.52 
 GH- PFC vs. SI-PFC 0.2303 
 
0.73 
GluN2B-CORT GH- HP vs. GH-PFC 0.7193 
 
0.70 
 SI-HP vs. SI- PFC 0.5879 
 
0.43 
 GH- HP vs. SI- HP 0.1143 
 
1.37 
 GH- PFC vs. SI-PFC 0.3916 
 
0.56 
GluN2B-CORT+LP12 GH- HP vs. GH-PFC 0.8352 
 
0.28 
 SI-HP vs. SI- PFC 0.8667 
 
0.17 
 GH- HP vs. SI- HP 0.3810 
 
0.65 





4.5.5. Inter-sex comparisons 
This section will focus solely on male vs. female comparisons in TrkB-Y816 transactivation, as 
well as CORT and CORT+LP12 TrkB-Y816 activation.  
Figure 40. male and female comparisons for TrkB-Y816 transactivation. HP and PFC slices were 
treated with 300 nM LP12 for 2 h, the slices were homogenized and samples evaluated by Western 
blots as described in the methods. The pTrkB data were normalized to total TrkB expression and 
are expressed as the fold change in phospho-Y816 immunoreactivity. The Mann-Whitney U test 
was used to compare sex differences in each region (males vs. females): GH-HP, p = 0.13; GH-
PFC, p = 0.86; SI-HP, p = 0.85; SI-PFC, p = 0.93. 
The greatest difference was observed in the GH-HP, wherein TrkB-Y816 phosphorylation 
was greater in the male samples than the female samples. In the GH-PFC group, there was no 
transactivation observed in either male, or female tissue. Comparing male and female data for SI-
HP and SI-PFC, it is evident that they have similar values, suggesting that the effect of isolation 
stress on TrkB-Y816 transactivation does not vary by sex. Furthermore, some degree of 
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transactivation seems to be present in SI-HP groups, but not the SI-PFC ones. Overall, 
transactivation is observed in male HP tissue from both housing conditions, but is observed only 
in female tissue from the SI-HP group. A two-way ANOVA was conducted to explore if there was 
any interaction between sex and housing within a given brain region (i.e., comparing 
males/females vs. GH/SI in either HP, or PFC); overall, no interactions were observed. 
 
 
Figure 41. male and female comparisons for CORT activation of the TrkB-Y816 receptor. HP and 
PFC slices were treated with 300 nM CORT for 1 h, the slices were homogenized and samples 
evaluated by Western blots as described in the methods. The pTrkB data were normalized to total 
TrkB expression and are expressed as the fold change in phospho-Y816 immunoreactivity 
(Wilcoxon Signed Rank Test) compared to non-treated control. The Mann-Whitney U test (* = p 
< 0.05) was used to compare sex differences in each region (males vs. females): GH-HP, p = 0.54; 
GH-PFC: p = 0.89; SI-HP: p = 0.93; SI-PFC: p = 0.013. 
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The data suggest that the difference in TrkB-Y816 activation caused by CORT treatment 
is statistically significant in only the SI-PFC group (p = 0.013). Overall, the male and female 
comparisons for the GH-HP, SI-HP and GH-PFC conditions suggest that CORT activation of 
phospho-Y816 does not vary by sex. A two-way ANOVA was conducted to explore if there was 
any interaction between sex and housing within a given brain region (e.g., comparing 
males/females vs. GH/SI in HP); overall, no interaction was observed. 
 
 
Figure 42. male and female comparisons for CORT+LP12 activation of the TrkB-Y816 residue. 
HP and PFC slices were treated with 300 nM CORT for 1 h, the slices were homogenized and 
samples evaluated by Western blots as described in the methods. The pTrkB data were normalized 
to total TrkB expression and are expressed as the fold change in phospho-Y816 immunoreactivity 
(Wilcoxon Signed Rank Test) compared to non-treated control. The Mann-Whitney U test (* = p 
< 0.05) was used to compare sex differences in each region (males vs. females): GH-HP, p = 
0.016; GH-PFC: p = 0.26; SI-HP: p = 0.23; SI-PFC: p = 0.99. 
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These data suggest that female HP tissue has a higher CORT+LP12-induced TrkB-Y816 
activation than male HP tissue, particularly in the GH-HP group (p = 0.016). The high p value (p 
= 0.99) in the SI-PFC suggests that there is no difference between male and female groups in that 
condition. Overall, these findings suggest that CORT+LP12 activation appears to differ by sex in 
all conditions except the SI-PFC.  A two-way ANOVA was conducted to explore if there was any 
interaction between sex and housing within a given brain region (e.g., comparing males/females 
vs. GH/SI in HP), and, overall, no interaction was observed; however, a statistically significant 
effect of sex (p = 0.025) was observed in the HP. 
In summary, LP12 and CORT data seem comparable across male and female tissue for 
most groups, suggesting that TrkB-Y816 activation is not sex specific. CORT+LP12 data were 
more variable, and overall outcomes differed by sex and region. Overall, the male and female 
comparison show that transactivation is observed in male HP (for both the GH and SI groups), but 
is only observed in female SI-HP tissue, suggesting that transactivation may be independent of 













The aim of this study was to evaluate within a given sex the impact of housing condition (group 
housed, GH vs. socially isolated, SI) on whether the treatments (LP12, CORT and CORT + LP12) 
affected transactivation, TrkB expression, or GluN2B expression. Additionally, I also sought to 
explore if there would be any region-specific differences in the outcomes. Based on previous 
findings, I hypothesized that I would observe: (i) sex-specific differences, (ii) region specific 
differences, (iii) that I would be able to replicate transactivation in male slices (in line with chapter 
2 findings), and (iv) that I would observe transactivation in female slices.  
4.6.1. TrkB-Y816 Activation in male animals  
The male data suggest that transactivation may occur in the GH-HP and SI-HP regions but there 
is no evidence of such an effect in the PFC. The observed changes seem to be more dependent on 
brain region than housing condition, which suggests that social isolation may not affect LP12-
induced 5-HT7 transactivation of the TrkB receptor observed at 2 h. It is imperative that this 
finding is not generalized to all forms of transactivation, as shifting parameters (for instance, 
treatment time, agonist concentration, initiating GPCR and target RTK) could change this 
outcome. To further clarify our outcomes, the sample size should be increased to see if the 
threshold for statistical significance will be crossed for some of our groups that displayed a null 
finding. Additionally, the magnitude of transactivation is generally modest which can make 
observing an effect challenging.  
If the current findings do indeed turn out to be the trend, the benefit would be that 
transactivation, which is a neuroprotective pathway, could be stable, and that various molecular 
changes that come with stress would not hinder, or affect the pathway. Another question that needs 
to be explored concerns the factors contributing to the observed region specificity. For example, 
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could receptor abundance, co-expression of various receptors, or other mediators be important? 
These answers would be imperative to explore in future studies to gain a clearer understanding of 
the therapeutic relevance of this pathway. The combined CORT+LP12 treatment shows an 
increase in the GH-PFC condition, showing that co-treatment with two agonists that activate TrkB-
Y816 has the capacity to induce PFC activation, even when the compounds had no effect on their 
own. These findings support our hypothesis, which stipulates that we would observe region 
specific differences in TrkB-Y816 activation in males.  
4.6.2. TrkB-Y816 Activation in female rats 
The hypothesis was that transactivation would be observed in female animals. The findings reflect 
that there appears to be LP12 transactivation in only one group (the SI-HP), which suggests a 
housing specific difference in the HP. In line with this argument, there is a possibility that this 
outcome could be a priming effect, in which transactivation is not observed in non-stressed rats, 
but activated in stress-exposed slices. Further, I observed that CORT modestly increases TrkB-
Y816 activation in hippocampal slices from the GH. Given that TrkB-Y816 activation was not 
observed in the GH-HP following LP12 treatment (but it was observed in SI-HP), but that CORT 
treatment induced TrkB-Y816 activation in the GH-HP, acute stress could influence TrkB-Y816 
activation in female HP tissue. CORT+LP12 treatment causes a significant increase in TrkB-Y816 
in the GH-HP, and a modest increase in SI-HP, whilst no change was observed in the PFC; these 
outcomes appear to be independent of housing conditions. In line with what was observed in male 
tissue, it appears that there is a region-specific change in females as TrkB-Y816 activation is 
primarily observed in the HP and not the PFC.   
Reflecting on my original hypothesis, it is important to note that this is the first time I 
attempted to characterize transactivation in female rat slices, and thus the parameters used were 
129 
 
those optimized in male animals. The rationale behind this decision was the desire to explore sex-
specific differences, based on findings in Chapter 3 that demonstrated sex-specific differences in 
response to TrkB and GluN2B expression changes. Additionally, I hypothesized that since female 
brains possess the required receptors (5-HT7 and TrkB), I should be able to observe transactivation 
in female slices. Eighteen months of preliminary data were collected before transactivation could 
be optimized in male slices, meaning that even though I observed transactivation in one region, it 
is a notable achievement that it was achieved on the first attempt. By that same token, similar 
characterization efforts may be required with female tissue. Therefore, the limited transactivation 
might be a function of the experimental conditions rather than the biological relevance. Increasing 
the sample size and exploring various concentrations of transactivating partners would be 
beneficial in understanding this outcome, and help to adequately interpret the female findings.  
4.6.3. Sex-specific differences 
Male and female rats have been shown to have different thresholds in their capacity to cope with 
stress, as well as differences in the behavioral manifestation of their stress response [286]. 
Differences in stress adaptability reported between male and female animals could underlie 
different changes in neurotransmission and neuronal structures. Based on this rationale, I 
hypothesized that I would observe sex specific differences; specifically, I anticipated that there 
would be a difference in the magnitude, or direction of effects. Surprisingly, the male and female 
data were comparable across many of the conditions in LP and CORT treatments, suggesting the 
effect to be more dependent on brain region and/or housing condition than sex. Given our p value 
thresholds, for TrkB-Y816 transactivation we are unable to reject the null hypothesis that there is 
no difference between female and male tissue. For CORT treatment a significant difference was 
observed in SI-PFC; likewise, for CORT+LP12 a significant difference was observed in the GH-
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HP, but overall no difference was observed for all other CORT, or CORT+LP12 treatment 
conditions. 
Since CELSI is an established rodent stressor, which has been shown to induce behavioral, 
structural and neurochemical changes in rodent brains [223], this finding does not bring into 
question the ability of CELSI to induce stress, rather it might be a reflection on the stability of the 
TrkB transactivation pathway against stress. 
4.6.4. Does stress have a priming effect on the brain, as is observed by CORT treatment?  
One of my aims was to explore if CELSI, an in vivo model of stress, would have a “priming” effect 
on HP and PFC slices that would pre-dispose them to respond differently to an acute stressor 
compared to non-stressed slices. To address this question, I chose to maintain TrkB-Y816 as our 
read-out, due to evidence in the literature [254, 302, 303, 305] that TrkB can be activated by stress. 
Additionally, my own CELSI treatments in slice showed that CORT can activate TrkB. Looking 
at the CORT data for male and female slices respectively, there is some possibility of mild priming 
effects. For the female rats, this was discussed in section 4.6.2. For the male rats, social isolation 
appears to decrease TrkB-Y816 activation in both the HP and PFC, although this outcome is 
statistically significant only in the latter group. Further, when looking at the intra-region and intra-
housing comparisons, the SI-HP vs. SI-PFC, and GH-PFC vs. SI-PFC have large effect sizes, 
suggesting that the magnitude of the observed differences may have biological significance.  
4.6.5. GluN2B and TrkB expression data 
TrkB expression 
In males, LP12 treatment and CORT treatment generally had limited to no effect on TrkB 
expression. On the contrary, CORT+LP12 data shows a general decrease in TrkB expression 
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compared to untreated controls in both GH and SI groups. In females, LP12 treatment and CORT 
treatment either had no effect or induced a decrease in TrkB expression.  
The outcomes in which treatment has no effect on expression may be an indicator that the 
given treatments (drug concentration and duration of treatment) are not sufficient to induce 
changes in receptor expression in slice. To better understand these results it would be essential to 
evaluate the corresponding changes in the BDNF protein, as for instance, this downregulation of 
TrkB could be in response to a significant increase in BDNF.  
GluN2B expression 
In males, LP12 treatment induces changes in GluN2B expression in the GH but no change was 
observed in the SI. Further, the data suggests that CORT has no effect on GluN2B expression in 
the GH group; but significant changes were observed in SI groups. The CORT+LP12 data suggest 
that there may be no change in GluN2B expression. In females, LP12 treatment generally had no 
effect on GluN2B expression. For CORT treatment as well as CORT+LP12 treatment opposite 
trends are observed in SI vs. GH groups for GluN2B expression. A predominant trend reflected in 
both the male and female data is the contrasting outcomes observed between GH and SI, suggesting 
that social isolation may have a priming effect that results in different outcomes to drug treatment.   
4.6.6. Summary of findings 
In summary, our findings of this study suggest that CELSI does not significantly affect 
transactivation, that there are minimal sex-specific effects, and limited priming effects, and that 
the major determinant of outcome is region. Overall, these outcomes make a powerful case for the 
therapeutic potential of a transactivation, since the pathway demonstrates such stability in the face 





This thesis had three major aims; the foundational goal was to replicate transactivation in a more 
physiologically relevant model. We achieved this by demonstrating reliable replication of 
transactivation with 300 nM LP12 for 2 h. This finding laid the foundation for subsequent studies 
that were focused on exploring the impact of stress on transactivation. The second aim of this 
thesis was to explore the impact of stress on plasticity related proteins, specifically, the TrkB and 
GluN2B proteins. Our findings show that CELSI affected TrkB and GluN2B receptor expression 
in a region and sex specific manner. 
  Having captured the changes in expression, the next step was to understand how CELSI 
affects receptor cross-talk. Given that TrkB and GluN2B play a significant role in neuronal 
development and are involved in many forms of receptor crosstalk, we chose to study their 
activation, or expression in the context of a cross-talk pathway. The pathway that we chose to 
study was the 5-HT7-TrkB transactivation pathway. Transactivation has been shown to be 
neuroprotective, so we sought to understand how CELSI affects transactivation, and if there are 
CELSI induced priming effects that would affect response to a later-stage stressor. Our findings 
suggest that CELSI does not significantly affect transactivation, that there are minimal sex-specific 
effects, and limited priming effects, and that the major determinant of outcome is brain region. 
These findings make a powerful case for the therapeutic potential of a transactivation, since the 
pathway demonstrates such stability in the face of many factors.  
Overall, the four chapters of this thesis have addressed the questions that it sought to 
explore. Future directions include further studies to explore the mechanism by which stressors; 
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